

# CURRICULUM VITAE

1. **Date:** April 25, 2016

## **I. PERSONAL**

2. **Name:** Alan Pollack, M.D., Ph.D.
3. **Office Phone:** 305-243-4916
4. **Current Academic Rank:** Professor and Chairman
5. **Primary Department:** Radiation Oncology
6. **Secondary or Joint Departmental Appointments:** N/A
7. **Citizenship:** U.S. Citizen
8. **Visa Type (if non-citizen):** N/A

## **II. HIGHER EDUCATION**

9. **Institutional (institution; degree; date conferred):**

University of Florida Gainesville, Florida	B.S. (Chemistry)	07/70 – 06/74
University of Miami Miami, Florida	Ph.D. (Microbiology & Immunology) “Radiation damage from radiolabeled compounds in stimulated lymphocytes”	08/75 – 12/79
University of Miami School of Medicine Miami, Florida	M.D.	07/85 – 06/87

10. **Non-Institutional:**

Jackson Memorial Hospital Miami, Florida	Internship Internal Medicine	06/87 – 06/88
University of Texas - M.D. Anderson Cancer Center Houston, Texas	Residency Radiation Therapy	07/88 – 06/92

11. **Certification, licensure:**

<u>Certification:</u> American Board of Radiology (Therapeutic Radiology)	06/93
--	-------

<u>Licensure:</u>	
Florida	2008-Present
Texas	1992-2003
Pennsylvania	1991-2008

### **III. EXPERIENCE**

#### **12. Academic (institutions; rank/status; dates):**

Papanicolaou Cancer Res. Inst. Miami, Florida	Research Assistant	1975-1976
Univ. of Miami Sch. of Med. Dept. of Microbiology Miami, Florida	Graduate Research Assist.	1976-1979
Univ. of Miami Sch. of Med. Dept. of Microbiology General Microbiology Lab. Miami, Florida	Graduate Teaching Assist.	1977
Veterans Admin. Med. Center Surgical Immunology Lab. Miami, Florida	Research Health Scientist	1979-1985
Univ. of Miami Sch. of Med. Department of Surgery Miami Florida	Adjunct Assistant Professor	1980-1983
Univ. of Miami Sch. of Med. Dept. of Microbiol. & Immunol. Miami, Florida	Adjunct Assistant Professor	1982-1984
Univ. of Miami Sch. of Med. Department of Surgery Miami, Florida	Research Assistant Professor	1983-1985
University of Texas - M.D. Anderson Cancer Center Dept. of Radiation Onc. Houston, Texas	Assistant Professor	1992-1995
University of Texas - M.D. Anderson Cancer Center Dept. of Radiation Oncology Houston, Texas	Associate Professor	1995-1999
University of Texas Grad. Sch. of Biomed. Sci. Houston, Texas	Regular Member of the Graduate Faculty	1995-2001

University of Texas - M.D. Anderson Cancer Center Dept. of Radiation Oncology Houston, Texas	Term Tenure	1998-2001
University of Texas - M.D. Anderson Cancer Center Dept. of Radiation Oncology Houston, Texas	Professor	1999-2001
Fox Chase Cancer Center Dept. of Radiation Oncology Philadelphia, PA	Senior Member & Chairman	2001-2008
University of Miami Sylvester Comprehensive Cancer Center Dept. of Radiation Oncology Miami, FL	Associate Director of Community Professional Relations	2008-2011
University of Miami Miller School of Medicine Dept. of Radiation Oncology Miami, FL	Tenured Professor and Chair	2008-Present
Jackson Memorial Medical Center Dept. of Radiation Oncology	Service Chief	2008-Present
University of Miami Hospital and Clinic (UMHC) Dept. of Radiation Oncology	Service Chief	2008-Present
University of Miami Hospital (UMH) Dept. of Radiation Oncology	Service Chief	2008-2009
University of Miami Hospital (UMH) Dept. of Radiation Oncology	Service Chief	2011-2013

**Visiting Professorships:**

Medical College of Georgia Dept. of Radiation Oncology Augusta, Georgia	Visiting Professor	1995 (Dec 6)
Stony Brook Sch. of Medicine Dept. of Radiation Oncology Stony Brook, New York	Visiting Professor	1998 (Feb 4)

Perth, Melbourne, Adelaide Several Centers of Radiation Oncology, Australia	Visiting Professor	1999 (May 14–22)
Fox Chase Cancer Center Dept. of Radiation Oncology Philadelphia, PA	Visiting Professor	2000 (Apr 12)
University of Pennsylvania Dept. of Radiation Oncology Philadelphia, PA	Visiting Professor	2001 (Sept 26)
Princess Margaret Hospital Dept. of Radiation Oncology Toronto, Canada	Visiting Professor	2002 (Feb. 21)
University of Virginia Dept. of Radiation Oncology Charlottesville, VA	Visiting Professor	2003 (Mar. 7)
Baylor College of Medicine Dept. of Radiation Oncology Houston, TX	Visiting Professor	2003 (May 23)
University of Chicago Dept. of Radiation Oncology Chicago, IL	Visiting Professor	2004 (Nov 15)
Henry Ford Health System Dept. of Radiation Oncology Detroit, MI	Visiting Professor	2005 (Jan 7)
University of Michigan Dept. of Radiation Oncology Ann Arbor, MI	Visiting Professor	2006 (Sept 18)
Southwestern Medical Center Dept. of Radiation Oncology Dallas, TX	Visiting Professor	2006 (Sept 29)
Geisinger Health System Dept. of Urology 100 North Academy Avenue Danville, PA	Visiting Professor	2007 (Jan 18)
MD Anderson Cancer Center Dept. of Radiation Oncology Houston, TX	Visiting Professor	2007 (Feb 21)
Montefiore Medical Center	Visiting Professor	2007 (Apr 26)

Dept. of Radiation Oncology Bronx, NY		
Mayo Clinic Dept. of Radiation Oncology Rochester, MN	Visiting Professor	2008 (Mar 7)
New York Presbyterian Hospital Dept. of Radiation Oncology New York, NY	Visiting Professor	2008 (Oct 24)
UT Health Science Center Dept. of Radiation Oncology San Antonio, TX	Visiting Professor	2009 (Aug 21)
Moffitt Cancer Center Dept. of Radiation Oncology Tampa, FL	Visiting Professor	2011 (Mar 4)
Emory University Dept. of Radiation Oncology Atlanta, GA	Visiting Professor	2013 (July 10)
University of Pennsylvania Dept. of Radiation Oncology Philadelphia, PA	Visiting Professor	2013 (Nov 5)
Columbia University Dept. Radiation Oncology New York, NY	Visiting Professor	2014 (Nov 14)
Tufts University Dept. of Radiation Oncology Boston, MA	Visiting Professor	2015 (Sept 18)

**13. Hospital Appointments (institutions, dates):**

University of Texas – M.D. Anderson Cancer Center Houston, TX		7/1988-6/2001
Fox Chase Cancer Center Philadelphia, PA		6/2001-5/2008
Sylvester Comprehensive Cancer Center University of Miami Hospital and Clinics Miami, FL		9/2008-Present
Jackson Memorial Medical Center Miami, FL		9/2008-Present

University of Miami Hospital  
Miami, FL

9/2008-Present

Anne Bates Leach Eye Hospital-  
Bascom Palmer Eye Institute  
Miami, FL

06/2008-Present

**14. Non-Academic (employers; title; responsibilities; dates): N/A**

**15. Military (branch; rank; responsibilities; dates): N/A**

## **IV. PUBLICATIONS:**

### **16. Books, Monographs, Book Chapters, Invited articles and Review Articles published:**

(\*Senior author of a resident or fellow)

1. **Pollack A**, Block NL, Irvin GL, Moulis A, Prudhomme DL. Flow cytometric analysis of cell kinetic responses using measurements of correlated DNA and nuclear protein. In: M Andreef (ed.), Clinical Cytometry, Annals of the New York Academy of Sciences Volume 468, pp. 55-66, 1986.
2. **Pollack A**, Ciancio G. Multiparameter cell cycle analysis of G2 blockade and cell death following irradiation. In: A Yen (ed.), Flow Cytometry: Advanced Research and Clinical Applications. Volume II, CRC Press, Inc., Boca Raton, FL, pp. 29-48, 1989.
3. **Pollack A**, Ciancio G. Cell cycle phase specific analysis of cell viability using Hoechst 33342 and propidium iodide after ethanol preservation. In: HA Crissman and Z Darzynkiewicz (eds.), Methods in Cell Biology, Academic Press, Inc., San Diego, CA, Volume 33, pp. 19-24, 1990.
4. **Pollack A**. Flow cytometric cell kinetic analysis by simultaneously staining nuclei with Propidium Iodide and Fluorescein Isothiocyanate. In: HA Crissman and Z Darzynkiewicz (eds.), Methods in Cell Biology, Academic Press, San Diego, CA, 1990, Volume 33, pp. 315-323.
5. Hall MC, **Pollack A**, Dinney CPN. Management of organ-confined bladder cancer. In: SN Rous (ed.), Urology Annual, W.W. Norton & Company, New York, NY, Volume 10, pp. 93-106, 1996.
6. Loehrer P, Ahlering T, **Pollack A**. Testicular seminomas. In: R Pazdur, L Coia, L Wagman, W Hoskins (eds.), Cancer Management: A Multidisciplinary Approach. PRR Treatment Handbook. PRR, Huntington, NY, (Chapter 18 2000 edition) pp. 329-345, 1997 (also 1998, 1999, & 2000 editions).
7. **Pollack A**, Hanks GE. Androgen ablation and radiotherapy for high risk prostate cancer. In: AV D'Amico and GE Hanks (eds.), Radiotherapeutic Management of Prostate Adenocarcinoma. Chapman & Hall, New York, NY, Volume 1, pp. 167-180, 1999.
8. **Pollack A**, Zagars GK. Pre-treatment prognostic factors for prostate cancer patients treated with external beam radiotherapy. In: C Greco and MJ Zelefsky (eds.), Radiotherapy of Prostate Cancer. Harwood Academic Publishers, Singapore, Chapter 10, pp. 113-128, 2000.
9. Hunt KK, Patel SR, **Pollack A**. Soft tissue sarcomas. In: MH Torosian and M Dekker, (eds.), Integrated Cancer Management: Surgery, Medical Oncology and Radiation Therapy. New York, NY, Chapter 16, pp. 394-415, 2000.
10. Yasko A, Patel S, **Pollack A**, Pollock, R. Sarcomas of soft tissue and bone. In: ACS Manual of Clinical Oncology, 2<sup>nd</sup> ed. Chapter 26 pp. 611-631, 2000.
11. **Pollack A**, Smith, L. MD Anderson prostate 3-D CRT experience. In: JA Purday, WH Grant III, J Palta, EB Buter, C Perez (eds.) 3-D Conformal and Intensity Modulated Radiation Therapy: Physics and Clinical Applications. Advanced Medical Publishing, Inc., Madison, WI, 2001.
12. \*Ballo MT, Shadle K, **Pollack A**. Radiotherapy in the management of seminoma. In: SS Donley (ed.), Atlas of Genitourinary Oncology. W.B. Saunders Company, Philadelphia, PA, 2002.
13. **Pollack A**, Smith LG. Adjuvant external beam radiation therapy postprostatectomy. In: AV D'Amico, P Carroll, PW Kantoff (eds.), Prostate Cancer. Lippincott Williams & Wilkins, Philadelphia, PA, pp 445-463, 2002.

14. Loehrer PJ, Ahlering TE, **Pollack A**. Testicular cancer. In: R Pazdur, LR Coia, WJ Hoskins, LD Wagman (eds.), Cancer management: a multidisciplinary approach. PRR, Melville, Kentucky, pp 351-369, 2002.
15. **Pollack A**. The prostate: In: JD Cox, KK Ang (eds), Moss' radiation oncology, rationale, technique, results, Eighth Edition. Mosby, St. Louis, MO, pp 629-678, 2003.
16. **Pollack A**, Horwitz EM, Movsas B, Hanlon AL. Mindless or mindful? Radiation oncologists' perspective on the evolution of prostate cancer. In: A. Krongrad (ed.), Urologic Clinics of North America, WB Saunders, Philadelphia, PA, pp. 337-349, 2003.
17. **Pollack A**, Price RA. IMRT for prostate cancer. In: JR Palta and TR Mackie (eds.), Intensity-Modulated Radiation Therapy The State of the Art. Medical Physics Publishing, Madison, WI, pp 617-630, 2003.
18. Loehrer PJ, Ahlering TE, **Pollack A**. Testicular cancer. In: R Pazdur, LR Coia, WJ Hoskins, LD Wagman (eds.), Cancer Management: A Multidisciplinary Approach, Seventh Edition. The Oncology Group, New York, NY, pp 383-402, 2003.
19. Uzzo RG, Cairns P, Dulin N, Horwitz EM, **Pollack A**, Kolenko V. Tumor resistance to apoptosis: Mechanisms of evasion and implications for radiation and chemotherapeutic strategies. In: JF Finke and RM Bukowski (eds.), Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done. Humana Press, Inc., Totowa, NJ, pp 215-233, 2003.
20. **Pollack A.**, Price R, Dong L, Feigenberg S, Horwitz E. Intact prostate cancer: Overview In: AJ Mundt and JC Roeske (eds.), Intensity Modulated Radiation Therapy: A Clinical Perspective. BC Decker, Inc, Ontario, Canada, pp 436-448, 2005.
21. Price RA, Horwitz EM, Feigenberg SJ, **Pollack A**. Intact prostate cancer: Case study. In: AJ Mundt and JC Roeske (eds.), Intensity Modulated Radiation Therapy: A Clinical Perspective. BC Decker, Inc, Ontario, Canada, pp 459-463, 2005.
22. Feigenberg SJ, **Pollack A**, Price RA, McNeeley SW, Horwitz EM. Prostate. In: KS Clifford Chao, S Apisarnthanarax, G Ozyigit (eds.), Practical Essentials of Intensity Modulated Radiation Therapy, Second Edition. Lippincott Williams & Wilkins, Philadelphia, PA, pp 308-324, 2004.
23. Loehrer PJ, Ahlering TE, **Pollack A**. Testicular cancer. In: R Pazdur, LR Coia, WJ Hoskins, LD Wagman (eds.), Cancer Management: A Multidisciplinary Approach, Ninth Edition. The Oncology Publishing Group, Lawrence, KS, pp 407-427, 2005.
24. **Pollack, A**. Adjuvant and salvage radiotherapy post-prostatectomy. In: NJ Vogelzang, PT Scardino, WU Shipley, FMJ Debruyne, WM Linehan. (eds.), Comprehensive Textbook of Genitourinary Oncology Third Edition. Lippincott Williams & Wilkins, Baltimore, MD, pp 295-306, 2005.
25. \*Buyyounouski MK, Horwitz EM, Price RA, Feigenberg SJ, **Pollack A**. Prostate IMRT . In: Image-Guided IMRT. T Bortfeld, R Schmidt-Ullrich, W de Neve (eds.), Springer-Verlag Heidelberg, Germany, pp 391-410, 2006.
26. Buyyounouski MK and **Pollack A**. External Beam Radiotherapy for Prostate Cancer. In Atlas of the Prostate; 3rd Ed., PT. Scardino, KM Slawin (eds.), Current Medicine LLC, Philadelphia, USA, pp 193-213, 2006.
27. Horwitz EM, Feigenberg SJ, **Pollack A**. Initial management of high risk early stage prostate cancer: Radiation. In: Prostate Cancer – Principles and Practice. Kirby RS, Partin AW, Feneley M, and Parsons JK,( eds.) Boca Raton: Taylor & Francis, pp 855-863, 2006.
28. Abramowitz MC, **Pollack A**. Postprostatectomy radiation therapy for prostate cancer. Semin. Radiat. Oncol. 18:15-22, 2008.



29. D'Ambrosio DJ, **Pollack A**, Harris EE, Price RA Jr, Verhey LJ, Roach M 3rd, Demanes DJ, Steinberg ML, Potters L, Wallner PE, Konski A. Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70:671-77, 2008.
30. Roach M 3rd, Waldman F, **Pollack A**. Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer. 115(13 Suppl):3112-3120, 2009.
31. Abdel-Wahab M, **Pollack A**. Radiotherapy: encouraging early data for SBRT in prostate cancer. Nat Rev Urol. 6:478-9, 2009.
32. Michalski JM, Roach III M, Merrick G, Anscher MS, Beyer DC, Lawton CA, Lee WR, **Pollack A**, Rosenthal SA, Vijayakumar S, Carroll PR. ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer. Int.J Radiat Oncol Biol Phys. 74:667-72, 2009.
33. Abdel-Wahab M, **Pollack A**. Prostate cancer: Defining biochemical failure in patients treated with HIFU. Nat. Rev. Urol. 7:186-7, 2010.
34. Michalski JM, Roach M 3<sup>rd</sup>, Merrick G, Anscher MS, Beyer DC, Lawton CA, Lee WR, **Pollack A**, Rosenthal SA, Vijayakumar S, Carroll PR. ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology prostate. Int. J. Radiat. Oncol. Biol. Phys. 74:667-72, 2009.
35. Udayakumar T, Shareef MM, Diaz DA, Ahmed MM, **Pollack A**. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy. Semin. Radiat. Oncol. 20:258-66, 2010.
36. Iglesias A, Diaz A, Stoyanova R, **Pollack A**. Genitourinary Tumors: Overview In Image-Guided Radiation Therapy: A Clinical Perspective, Mundt AJ, Roeske JC, (eds.) Shelton: People's Medical Publishing House – USA, pp 349-365, 2011.
37. **Pollack A.** and Ahmed MM (eds.) Hypofractionation: scientific concepts and clinical experiences. Ellicott City: LumiText Publishing, 2011.
38. Abramowitz MC, **Pollack A**. Hypofractionated radiotherapy for prostate cancer: has the time come? Oncology (Wilson Park). 26:519-22, 2012.
39. Abramowitz MC, **Pollack A**. Radiation and Hormonal Decision Points in the Treatment of Biochemical Failure After Radical Prostatectomy. Radiation Oncology Difficult Cases and Practical Management. p 115, 2013.
40. Scott M, Orman A, **Pollack A**. Early Prostate Cancer (T1-2N0M0). Intensity-Modulated Radiation Therapy, Nishimura Y, Komaki R, (eds.) 19:355-77, 2015.

#### 17. Juried or refereed journal articles or exhibitions:

(\*Senior author of a resident or fellow)

1. Gratzner HG, **Pollack A**, Ingram DJ, Leif RC. Deoxyribonucleic acid replication in single cells and chromosomes by immunologic techniques. J. Histochem. Cytochem. 24:34-9, 1976.
2. **Pollack A**, Bagwell CB, Hudson JL, Irvin III GL. Differences in flow cytometry and <sup>3</sup>H-thymidine analyses of perturbed human lymphocytes. J. Histochem. Cytochem. 27:486-90, 1979.
3. **Pollack A**, Bagwell CB, Irvin III GL. Radiation from tritiated thymidine perturbs the cell cycle progression of PHA stimulated lymphocytes. Science 203:1025-7, 1979.
4. **Pollack A**, Bagwell CB, Irvin III GL and Jensen JA. The kinetics of the formation of a G2 block from <sup>3</sup>H-TdR in PHA stimulated human lymphocytes. Cytometry 1:57-64, 1980.

5. Collins JM, Bagwell CB, Block NL, Claflin AJ, Irvin III GL, **Pollack A**, and Stover B. Flow cytometric monitoring of R-3327 rat prostate carcinoma. Invest. Urol. 19:8-13, 1981.
6. **Pollack A**, Bagwell CB, Block NL, Irvin III GL, Stover BJ, Claflin AJ. Flow cytometric analysis of the response of the R3327-G rat prostatic adenocarcinoma to endocrine manipulation. J. Surg. Oncol. 18:389-98, 1981.
7. Claflin AJ, **Pollack A**, Malinin T, Block NL, Irvin III GL. Flow cytometric analysis of R3327 rat prostate adenocarcinoma grown in vitro and in vivo. J. Nat. Cancer Inst. 69:79-87, 1982.
8. **Pollack A**, Irvin III GL, Block NL, Stover BJ, Lipton RM, Claflin AJ. Hormone sensitivity of the R3327-G rat prostate carcinoma growth rate, DNA content, and hormone receptors. Cancer Res. 42:2184-90, 1982.
9. **Pollack A**, Prudhomme D, Greenstein D, Irvin III GL, Claflin AJ, Block NL. Flow cytometric analysis of RNA content in different cell populations using pyronin Y and methyl green. Cytometry 3:28-35, 1982.
10. **Pollack A**, Block NL, Stover BJ, Irvin III GL, Fuentes MP, Claflin AJ, Malinin TI. The in vivo selection of androgen-insensitive cells in R3327-G rat prostate tumors: Diethylstilbestrol diphosphate versus orchiectomy. J. Nat. Cancer Inst. 70:907-14, 1983.
11. **Pollack A**, Block NL, Stover BJ, Fuentes MP, Irvin III GL. Effects of the gonadotropin-releasing hormone GnRH agonist [D-leu-6, desgly-amino-10, pro-ethylamide-9]-GnRH (leuprolide) on R3327-G rat prostatic tumor growth. J. Urol. 131:399-403, 1984.
12. **Pollack A**, Moulis H, Block NL, Irvin III GL. Quantitation of cell kinetic responses using flow cytometry to simultaneously measure DNA and nuclear protein. Cytometry 5:473-81, 1984.
13. **Pollack A**, Block NL, Irvin III GL. Tumor progression in serial passages of the Dunning R3327-G rat prostatic adenocarcinoma: Growth rate response to endocrine manipulation. Cancer Res. 45:1052-7, 1985.
14. **Pollack A**, Moulis H, Greenstein DB, Block NL, Irvin III GL. Cell kinetic effects of incorporated <sup>3</sup>H-thymidine on proliferating human lymphocytes: Flow cytometric analysis using the DNA/nuclear protein method. Cytometry 6:428-36, 1985.
15. Sevin BU, **Pollack A**, Averette, HE, Ramos R, Greening SE, Evans D. In vivo chemosensitivity testing in patients with gynecologic malignancies and nude mouse xenografts by monitoring cell kinetic parameters and DNA distribution patterns: A preliminary report. Gynecol. Oncol. 24:27-40, 1986.
16. Sevin BU, **Pollack A**, Averette HE, Ramos R, Donato D. In vivo cell kinetic effects of Cis-platinum on human ovarian cancer xenografts using dual parameter flow cytometry. Cytometry 8:153-62, 1987.
17. \*Ciancio G, **Pollack A**, Taupier MA, Block NL, Irvin III GL. Measurement of cell cycle phase specific cell death using Hoechst 33342 and propidium iodide: Preservation by ethanol fixation. J. Histochem. Cytochem. 36:1147-52, 1988.
18. Wolloch EH, Sevin BU, Perras JP, Gottlieb CF, **Pollack A**, Ramos R, Schiano MA, Averette, HE. Cell kinetic perturbations after irradiation and caffeine exposure in BG-1 ovarian carcinoma cells. Gynecol. Oncol. 43:29-36, 1991.
19. **Pollack A**, El-Naggar A, Cox JD, Ro JY, Sahine A, Komaki R. Thymoma: The prognostic significance of flow cytometric DNA analysis. Cancer 69:1702-9, 1992.
20. **Pollack A**, Komaki R, Cox JD, Shin DM, Putnam W, Ro JY. Thymoma: Treatment and prognosis. The experience at UTMD Anderson Cancer Center. Int. J. Rad. Oncol. Biol. Phys. 23:1037-43, 1992.

21. **Pollack A**, Terry NHA, Van NT, Meistrich ML. Flow cytometric analysis of two incorporated halogenated thymidine analogues and DNA in a mouse mammary tumor grown in vivo. Cytometry 14:168-72, 1993.
22. \*Ciancio G, **Pollack A**, Block NL. Flow cytometric analysis of DNA and nuclear protein in paraffin-embedded tissue. Cytometry 14:205-9, 1993.
23. **Pollack A**, Ciancio G, Terry NHA, Block NL. Recognition and reduction of artifacts from autolysis in paraffin-embedded tissue using DNA/nuclear protein flow cytometry. Cytometry 14:565-8, 1993.
24. Zagars GK, **Pollack A**. The fall and rise of prostate-specific antigen: Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer 72:832-42, 1993.
25. **Pollack A**, White RA, Cao S, Meistrich ML, Terry NHA. Calculating potential doubling time using monoclonal antibodies specific for two halogenated thymidine analogues. Int. J. Rad. Oncol. Biol. Phys. 27:1131-9, 1993.
26. **Pollack A**, Terry NHA, White RA, Cao S, Meistrich ML, Milas L. Proliferation kinetics of recruited cells in a mouse mammary carcinoma. Cancer Res. 54:811-7, 1994.
27. \*Gauwitz MD, **Pollack A**, El-Naggar AK, Terry NHA, Zagars GK. The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 28:821-8, 1994.
28. **Pollack A**, Zagars GK, El-Naggar A, Gauwitz MD, Terry NHA. Near-Diploidy: A new prognostic factor for clinically localized prostate cancer treated with external beam radiotherapy. Cancer 73:1896-903, 1994.
29. Zagars GK, Geara FB, **Pollack A**, von Eschenbach AC. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome following radiation therapy. Cancer 73:1904-12, 1994.
30. Zagars GK, **Pollack A**. The serum prostate-specific antigen level three months after radiotherapy for prostate cancer: An early indicator of response to treatment. Radioth. Oncol. 30:121-7, 1994.
31. White RA, **Pollack A**, Terry NHA. Simultaneous cytokinetic measurement of aneuploid tumors and associated diploid cells following continuous labelling with chlorodeoxyuridine. Cytometry 15:311-9, 1994.
32. Zagars GK, Sands ME, **Pollack A**, von Eschenbach AC. Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: Prognostic variables and outcome. J. Urol. 151, 1330-3, 1994.
33. Park HE, Shin DM, Lee JS, Komaki R, **Pollack A**, Putnam JB, Cox JD, Hong WK. Thymoma. A retrospective study of 87 cases. Cancer 73:2491-8, 1994.
34. Sands ME, Zagars GK, **Pollack A**, von Eschenbach AC White RA, **Pollack A**, Terry NHA, Cao S, Meistrich ML. Double labelling to obtain S-phase subpopulations: Application to determine cell kinetics of diploid cells in an aneuploid tumor. Cell Prolif. 27:123-37, 1994.
35. Sands ME, Zagars GK, **Pollack A**, von Eschenbach AC. Serum prostate-specific antigen, clinical stage, pathologic grade and the incidence of nodal metastases in prostate cancer. Urology 44:215-20, 1994.
36. **Pollack A**, Zagars GK, Kavadi VS. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 74:670-78, 1994.
37. **Pollack A**, Zagars GK, Swanson DA. Muscle-invasive bladder cancer treated with external beam radiotherapy: Prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 30:267-77, 1994.

38. Geara FB, Zagars GK, **Pollack A**. Influence of initial presentation on treatment outcome of clinically localized prostate cancer treated by definitive radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 30:331-337, 1994.
39. Kavadi VS, Zagars GK, **Pollack A**. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications. Int. J. Radiat. Oncol. Biol. Phys. 30:279-87, 1994.
40. **Pollack A**, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC. Preoperative radiotherapy for muscle-invasive bladder cancer: Long term Follow-up and prognostic factors for 338 patients. Cancer 74:2819-27, 1994.
41. **Pollack A**, Zagars GK, El-Naggar A, Terry NHA. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer. Urology 44:711-18, 1994.
42. Hall MC, Troncoso P, **Pollack A**, Zhau HYE, Zagars GK, Chung LWK, von Eschenbach AC. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology 44:869-75, 1994.
43. \*Sands ME, **Pollack A**, Zagars GK. Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. Int. J. Radiat. Oncol. Biol. Phys. 31:13-9, 1995.
44. Zagars GK, Ayala AG, von Eschenbach AC, **Pollack A**. The prognostic importance of Gleason grade in prostatic adenocarcinoma: A long-term follow-up study of 648 patients treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 31:237-45, 1995.
45. Hall MC, Navone NM, Troncoso P, **Pollack A**, Zagars GK, von Eschenbach AC, Conti CJ, Chung LWK. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 45:470-75, 1995.
46. Zagars GK, **Pollack A**. Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome. Urology 45:476-83, 1995.
47. **Pollack A**, Zagars GK, Kopplin S. Radiotherapy and androgen ablation for clinically localized high risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:13-20, 1995.
48. **Pollack A**, Terry NHA, Wu CS, Wise BM, White RA, Meistrich ML. Specific staining of iododeoxyuridine and bromodeoxyuridine in tumors double-labelled in vivo: A cell kinetic analysis. Cytometry 20:53-61, 1995.
49. Zagars GK, Kavadi VS, **Pollack A**, von Eschenbach AC, Sands ME. The source of pre-treatment serum prostate-specific antigen in clinically localized prostate cancer - T, N, or M? Int. J. Radiat. Oncol. Biol. Phys. 32:21-32, 1995.
50. \*Cole CJ, **Pollack A**, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC. Local control of muscle-invasive bladder cancer: Preoperative radiotherapy and cystectomy versus cystectomy alone. Int. J. Radiat. Oncol. Biol. Phys. 32:331-40, 1995.
51. Zagars GK, **Pollack A**, Kavadi VS, von Eschenbach AC. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:293-06, 1995.
52. Zagars GK, **Pollack A**, von Eschenbach AC. Prostate cancer and radiation therapy - The message conveyed by serum prostate-specific antigen. Int. J. Radiat. Oncol. Biol. Phys. 33:23-5, 1995.
53. **Pollack A**, Zagars GK, Cole CJ, Dinney CPN, Swanson DA, Grossman HB. The relationship of local control to distant metastasis in muscle-invasive bladder cancer. J. Urol. 154:2059-64, 1995.
54. \*Lankford SP, **Pollack A**, Zagars GK. Radiotherapy for regionally localized hormone refractory prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 33:907-12, 1995.

55. **Pollack A**, Zagars GK, Starkschall G, Childress CH, Kopplin S, Boyer AL, Rosen II. Conventional versus conformal radiotherapy for prostate cancer: Preliminary results of dosimetry and acute toxicity. Int. J. Radiat. Oncol. Biol. Phys. 34:555-564, 1996.
56. \*Wu CS, **Pollack A**, Czerniak BA, Chyle V, Zagars GK, Dinney CP, Benedict WF. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology 47:305-10, 1996.
57. **Pollack A**, Lankford S, Zagars GK, Babaian RJ. PSA density as a prognostic factor in prostate cancer patients treated with radiotherapy. Cancer 77:1515-23, 1996.
58. Zagars GK, Mullen JR, **Pollack A**. Malignant fibrous histiocytoma: Outcome and prognostic factors following conservation surgery and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 34:983-94, 1996.
59. \*Chyle V, **Pollack A**, Czerniak B, Stephens LC, Zagars GK, Terry NHA, Meyn RE. Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int. J. Radiat. Oncol. Biol. Phys. 35:281-7, 1996.
60. Zagars GK, Goswitz MS, **Pollack A**. Liposarcoma: Outcome and prognostic factors following conservation surgery and radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 36:311-9, 1996.
61. Zagars GK, **Pollack A**, von Eschenbach AC. Serum Testosterone - A significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 49:327-34, 1996.
62. **Pollack A**, Troncoso P, Zagars GK, von Eschenbach AC, Mak AC, Wu CS, Terry NHA. The significance of DNA-ploidy and S-phase fraction in node-positive (Stage D1) prostate cancer treated with androgen ablation. Prostate 31:21-8, 1997.
63. **Pollack A**, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. Significance of downstaging in muscle-invasive bladder cancer treated with preoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 37:41-50, 1997.
64. Zagars GK, **Pollack A**, von Eschenbach AC. Prognostic factors in clinically localized prostate cancer. Analysis of 938 patients irradiated in the PSA era. Cancer 79:1370-80; 1997.
65. **Pollack A**, Joon DL, Wu CS, Sikes C, Hasegawa M, Terry NHA, White A, Zagars GK, Meistrich ML. Quiescence in R3327-G rat prostate tumors after androgen ablation. Cancer Res. 57:2493-500, 1997.
66. \*Lankford SP, **Pollack A**, Zagars GK. Prostate specific antigen cancer volume: A significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 38:327-33, 1997.
67. Zagars GK, **Pollack A**, von Eschenbach AC. Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer 80:764-75, 1997.
68. \*Lim Joon D, Hasagawa M, Sikes C, Khoo VS, Terry NHA, Zagars GK, Meistrich ML, **Pollack A**. Supra-additive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int. J. Radiat. Oncol. Biol. Phys. 38:1071-7, 1997.
69. Zagars GK, **Pollack A**. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radioth. Oncol. 44:213-21, 1997.
70. Zagars GK, **Pollack A**. Serum testosterone levels after external beam radiation for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 39:85-9, 1997.
71. **Pollack A**, Wu CS, Czerniak B, Zagars GK, Benedict WF, McDonnell TJ. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin. Cancer Res. 3:1823-9, 1997.
72. **Pollack A**, Czerniak B, Zagars GK, Hu SX, Wu CS, Dinney CPN, Chyle V, Benedict WF. Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer. Int. J. Radiat. Oncol. Biol. Phys. 39:687-95, 1997.

73. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, **Pollack A**, von Eschenbach AC, Davis D, Tu SM, Johnston D, Pathak S, Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin. Cancer Res. 3: 2493-2500, 1997.
74. **Pollack A**, Zagars GK. External beam radiotherapy dose-response of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 39:1011-1018, 1997.
75. Ciancio G, Viciano A, **Pollack A**, Lim Joon D, Wu CS, Ruiz P, Weppler D, Schiff E, Tzakis A. Flow cytometric DNA analysis of paraffin-embedded hepatocellular carcinoma from patients treated by orthotopic liver transplantation. Transplantation Proc. 29:2878-9, 1997.
76. Pisters PW, Patel SR, Varma DG, Cheng SC, Chen NP, Nguyen HT, Feig BW, **Pollack A**, Pollock RE, Benjamin RS. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: Long term results from a single institution. J. Clin. Oncol. 15:3481-7, 1997.
77. Westney OL, Pisters LL, Pettaway CA, Tu SM, **Pollack A**, Dinney DPN. Presentations, methods and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J. Urol. 159:792-5, 1998.
78. **Pollack A**, Zagars GK. External beam radiotherapy for stage T1/T2 prostate cancer: How does it stack up? Urology 51:258-64, 1998.
79. \*Ballo MT, Zagars GK, Pisters P, **Pollack A**. The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int. J. Radiat. Oncol. Biol. Phys. 40:823-7, 1998.
80. Nguyen LN, **Pollack A**, Zagars GK. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: Results of a self-assessment questionnaire. Urology 51:991-7, 1998.
81. Midis GP, Pollock RE, Chen NP, Feig BW, Murphy A, **Pollack A**, Pisters PWT. Locally recurrent soft tissue sarcoma of the extremities. Surgery 123:666-71, 1998.
82. \*Liebross RH, **Pollack A**, Lankford SP, von Eschenbach AC, Zagars GK. Relationship of ultrasound staging and bilateral biopsy positivity to outcome in stage T1c prostate cancer treated with radiotherapy. Urology 52:647-52, 1998.
83. Zagars GK, **Pollack A**, Pettaway CA. Prostate cancer in African-American men: Outcome following radiation therapy with or without adjuvant androgen ablation. Int. J. Radiat. Oncol. Biol. Phys. 42:517-23, 1998.
84. **Pollack A**, Zagars GK, Goswitz MS, Pollock RA, Feig BW, Pisters PWT. Preoperative versus postoperative radiotherapy in the treatment of soft tissue sarcomas: A matter of presentation. Int. J. Radiat. Oncol. Biol. Phys. 42:563-72, 1998.
85. Antolak JA, Rosen II, Childress CH, Zagars GK, **Pollack A**. Prostate target volume variations during a course of radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 42:661-72, 1998.
86. Ballo MT, Zagars GK, **Pollack A**. Radiation therapy in the management of desmoid tumors. Int. J. Radiat. Oncol. Biol. Phys. 42:1007-14, 1998.
87. \*Chaney AW, **Pollack A**, McNeese MD, Zagars GK. Adjuvant radiotherapy for phyllodes tumor of the breast. Radiat. Oncol. Invest. 6:264-7, 1998.
88. Ballo MT, Zagars GK, **Pollack A**, Pisters PWT, Pollock RA. Desmoid tumor: Outcome and prognostic factors following surgery, radiation, or combined surgery and radiation. J. Clin. Oncol. 17:158-67, 1999.
89. Pearlstone DV, Pisters PWT, Bold RJ, Feig BW, Hunt KK, Yasko AW, Patel S, **Pollack A**, Benjamin RS, Pollock RE. Patterns of recurrence in extremity liposarcoma: Implications for staging and follow-up. Cancer 85:85-92, 1999.

90. Hanus MC, Zagars GK, **Pollack A**. Familial prostate cancer: Outcome following radiation therapy with or without adjuvant androgen ablation. Int. J. Radiat. Oncol. Biol. Phys. 43:379-83, 1999.
91. \*Liebross RH, **Pollack A**, Lankford SP, Zagars GK, von Eschenbach AC, Geara FB. Transrectal ultrasound for staging prostate cancer prior to radiation therapy: An evaluation based on disease outcome. Cancer 85:1577-85, 1999.
92. Zagars GK, **Pollack A**, Smith LG. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/NO, MO) adenocarcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 44:809-19, 1999.
93. \*Khoo VS, **Pollack A**, Cowen D, Lim Joon D, Patel N, Terry NHA, Zagars GK, von Eschenbach AC, Meistrich ML, Troncso P. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate 41:166-72, 1999.
94. Fleming JB, Berman RS, Cheng SC, Chen NP, Hunt KK, Feig BW, Yasko AW, **Pollack A**, et al. Long-term outcome of patients with American Joint Committee on cancer stage IIB extremity soft tissue sarcomas. J. Clin. Oncol. 17:2772-80, 1999.
95. **Pollack A**, Ashoori F, Sikes C, Joon DL, von Eschenbach AC, Zagars GK, **Meistrich ML**. The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions. Int. J. Radiat. Oncol. Biol. Phys. 46:153-8, 1999.
96. \*Kelly J, **Pollack A**, Zagars GK. Serum testosterone is not a correlate of prostate cancer lymph node involvement, but does predict biochemical failure for lymph-node-positive disease. Urol. Oncol. 5:78-84, 2000.
97. Amato RJ, Millikan R, Daliani D, Wood L, Logothetis C, **Pollack A**. Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma. Clin. Cancer Res. 6:72-7, 2000.
98. **Pollack A**, Smith LG, von Eschenbach AC. External beam radiotherapy dose-response characteristics of 1127 men with prostate cancer treated in the PSA era. Int. J. Radiat. Oncol. Biol. Phys. 48:507-12, 2000.
99. White RA, Meistrich ML, **Pollack A**, Terry NHA. Simultaneous estimation of  $T_{G2+M}$ ,  $T_s$ , and  $T_{pot}$  using single sample dynamic tumor data from bivariate DNA-thymidine analogue cytometry. Cytometry 41:1-8, 2000.
100. \*Chaney AW, **Pollack A**, McNeese MD, Zagars GK, Pisters PWT, Pollock RE, Hunt KK. Primary treatment of cystosarcoma phyllodes of the breast. Cancer 2000 89:1502-11, 2000.
101. \*Storey MR, **Pollack A**, Zagars GK, Smith LG, Antolak J, Rosen I. Complications from dose escalation in prostate cancer: Preliminary results of a randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 48:635-42, 2000.
102. May CA, Tamika K, Neumann R, Wilson G, Zagars G, **Pollack A**, DubrovaYE, Jeffreys AJ, Meistrich ML. Minisatellite mutation frequency in human sperm following radiotherapy. Mut. Res. 453:67-75, 2000.
103. **Pollack A**, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J. Clin. Oncol. 18:3904-11, 2000.
104. \*Colletier PJ, Ashoori F, Cowen D, Toflin P, Meyn RE, Meistrich ME, **Pollack A**. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and mutant p53 prostate cancer cells in vitro to irradiation. Int. J. Radiat. Oncol. Biol. Phys. 48:1507-12, 2000.

105. \*Cowen D, Salem N, Ashoori F, Meyn R, Meistrich ML, Roth JA, **Pollack A**. Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. Clin. Cancer Res. 6:4402-8, 2000.
106. Starkschall G, **Pollack A**, Stevens CW. Treatment planning using a dose-volume feasibility search algorithm. Int. J. Radiat. Oncol. Biol. Phys. 49:1419-27, 2001.
107. Campbell T, Blasko J, Crawford ED, Forman J, Hank G, Kuban D, Montie J, Moul J, **Pollack A**, Raghavan D, Ray, Roach M III, et al. Clinical staging of prostate cancer: Reproducibility and clarification of issues. Int. J. Cancer (Radiat. Oncol. Invest. 96:198-209, 2001.
108. Zagars GK, **Pollack A**, von Eschenbach, A. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology 58:233-9, 2001.
109. **Pollack A**, Salem N, Ashoori F, Hachem P, Sangha M, von Eschenbach AC, Meistrich M. Lack of prostate cancer radiosensitization by androgen deprivation. Int. J. Rad. Oncol. Biol. Phys. 51:1002-7, 2001.
110. Zagars GK, **Pollack A**. Radiotherapy for stage II testicular seminoma. Int. J. Rad. Oncol. Biol. Phys. 51:643-9, 2001.
111. **Pollack A.**, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: Results of the MD Anderson phase III randomized trial. Int. J. Rad. Oncol. Biol. Phys. 53:1097-05, 2002.
112. \*Cowen D, Troncso P, Khoo V, Zagars GK, vonEschenbach AC, Meistrich M, **Pollack A**. KI-67 Staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin. Cancer Res. 8:1148-1154, 2002.
113. \*Huang E, Dong L, Chandra A, Kuban DA, Rosen II, Evans A, **Pollack A**. Intrafraction prostate motion during IMRT for prostate cancer. Int. J. Rad. Oncol. Biol. Phys. 53:261-8, 2002.
114. Rosser CJ, Kuban DA, Levy LB, Chichakli R, **Pollack A**, Lee AK, Pisters LL. The prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J. Urol. 168:2001-5, 2002.
115. **Pollack A**, Zagars GK, Antolak JA, Kuban DA, Rosen II. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: Analysis of a prostate cancer randomized radiation dose escalation trial. Int. J. Rad. Oncol. Biol. Phys. 54:677-85, 2002.
116. Huang E, **Pollack A**, Levy L, Starkschall G, Dong L, Rosen I, Kuban D. Late rectal toxicity: Dose-volume effects of conformal radiotherapy for prostate cancer. Int. J. Rad. Oncol. Biol. Phys. 54:1314-21, 2002.
117. Ryu JK, Winter K, Michalski JM, Purdy JA, Markoe AM, Earle JD, Perez CA, Roach M, Sandler HM, **Pollack A**, Cox JD. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, Level III (79.2 Gy). Int. J. Rad. Oncol. Biol. Phys. 54:1036-46, 2002.
118. Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, Hanks GE, **Pollack A**. Hypoxic prostate/muscle pO<sub>2</sub> ratio predicts for biochemical failure in patients with prostate cancer: Preliminary findings. Urology 60:634-9, 2002.
119. **Pollack A**, Cowen D, Troncso P, Zagars GK, von Eschenbach AC, Meistrich ML, McDonnell T. Molecular markers of patient outcome in prostate cancer treated with radiotherapy: Ki-67, Bcl-2, Bax, and Bcl-x. Cancer 97:1630-38, 2003.
120. **Pollack A**, Grignon DJ, Heydon KH, Hammond EH, Lawton CA, Mesic JB, Fu KK, Porter AT, Abrams RA, Shipley WU. Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: An analysis of RTOG 8610. J. Clin. Oncol. 21:1238-48, 2003.



121. Uzzo RG, Pinover WH, Horwitz EM, Parlanti A, Mazzoni S, Raysor S, Mirchandani I, Greenberg RE, **Pollack A**, Hanks GE, Watkins-Bruner D. Free Prostate-Specific Antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digital rectal examination. Urology 61:754-9, 2003.
122. Michalski JM, Winter K, Purdy JA, Wilder RB, Perez CA, Roach M, Parliament MB, **Pollack A**, Markoe AM, Harms W, Sandler HM, Cox JD. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int. J. Radiat. Oncol. Biol. Phys. 56:192-8, 2003.
123. Rosser CJ, Levy LB, Kuban DA, Chichakli R, **Pollack A**, Lee AK, Pisters LL. Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostate. J. Urol. 169:2160-5, 2003.
124. Horwitz EM, Uzzo RG, Hanlon AL, Greenberg, RE, Hanks, GE, **Pollack A**. Modifying American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone. J. Urol. 169:2153-9, 2003.
125. Chandra A, Dong L, Huang E, Kuban DA, O'Neill L, Rosen I, **Pollack A**. Evaluation of ultrasound-based daily prostate localization. Int. J. Radiat. Oncol. Biol. Phys. 56:436-47, 2003.
126. D'Souza WD, Lee HK, Palmer MB, Smith LG, **Pollack A**. Is intraoperative nomogram-based overplanning of prostate implants necessary? Int. J. Radiat. Oncol. Biol. Phys. 56:462-7, 2003.
127. \*Taylor NA, Kelly JF, Kuban DA, Babaian RJ, Pisters LL, **Pollack A**. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 56:755-63, 2003.
128. \*Chism DB, Hanlon, AL, Troncoso P, Al-Saleem T, Horwitz EM, **Pollack A**. The Gleason score shift: Score four and seven years ago. Int. J. Rad. Oncol. Biol. Phys. 56: 1241-7, 2003.
129. \*Buyyounouski MK, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE, **Pollack A**. Positive prostate biopsy laterality and implications for staging. Urology 62:298-303, 2003.
130. **Pollack A**, Hanlon AL, Movsas B, Hanks GE, Uzzo R, Horwitz EM. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 57:19-23, 2003.
131. \*Kaminski JM, Hanlon AL, Joon DL, Meistrich M, Hachem P, **Pollack A**. Effect of sequencing androgen deprivation and radiation on prostate cancer growth. Int. J. Radiat. Oncol. Biol. Phys. 57:24-8, 2003.
132. Diefenbach, MA, Hamrick, N, Uzzo, R, **Pollack, A**, Horwitz, E, Greenberg, R, Engstrom, PE. Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with early-stage prostate cancer. J. of Urology 170:166-9, 2003.
133. Chakravarti A, Heydon K, Wu CL, Hammond **E**, **Pollack A**, Roach M, Wolkov H, Okunieff P, Cox J, Fontanesi J, Abrams R, Pilepich M, Shipley W. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: An analysis from the Radiation Therapy Oncology Group Protocol 86-10. J. Clin. Oncol. 21:3328-34, 2003.
134. Lee HK, D'Souza WD, Yamal MJ, **Pollack A**, Lee AK, Palmer B, Kuban DA. Dosimetric consequences of using a surrogate urethra to estimate urethral dose after brachytherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 57:355-61, 2003.

135. \*Nguyen KH, Horwitz EM, Hanlon AL, Uzzo RG, **Pollack A**. Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 57:377-83, 2003.
136. Price RA, Murphy S, McNeeley SW, Ma CM, Horwitz E, Movsas B, Raben A, **Pollack A**. A method for increased dose conformity and segment reduction for sMLC delivered IMRT treatment of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 57:843-52, 2003.
137. \*Little DJ, Kuban DA, Levy LB, Zagars GK, **Pollack A**. Quality-of-Life Questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology 62:707-13, 2003.
138. Kuban D, **Pollack A**, Huang E, Levy L, Dong L, Starkschall G, Rosen I. Hazards of dose escalation in prostate cancer radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 57:1260-8, 2003.
139. Hanlon AL, Horwitz EM, Hanks GE, **Pollack A**. Short-term androgen deprivation and PSA doubling time: Their association and relationship to disease progression after radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 58:43-52, 2004.
140. Watkins Bruner D, Hanlon A, Mazzoni S, Raysor S, Konski A, Hanks G, **Pollack A**. Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 58:34-42, 2004.
141. \*Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, **Pollack A**. The relationship of increasing radiotherapy dose to reduced distant metastasis and mortality in men with prostate cancer. Cancer 100:538-43, 2004.
142. \*Mu Z, Hachem P, Agrawal S, **Pollack A**. Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination. Int. J. Radiat. Oncol. Biol. Phys. 58:336-43, 2004.
143. \*Buyyounouski MK, Horwitz EM, Price RA, Hanlon AL, Uzzo RG, **Pollack A**. Intensity-modulated radiotherapy with MRI Simulation to reduce doses received by erectile tissue during prostate cancer treatment. Int. J. Radiat. Oncol. Biol. Phys. 58:743-9, 2004.
144. **Pollack A**, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE. Prostate cancer radiotherapy dose response: An update of the Fox Chase experience. J. Urol. 171:1132-6, 2004.
145. Paskalev K, Ma C-M, Jacob R, Price R, McNeeley S, Wang L, Movsas B, **Pollack A**. Daily target localization for prostate patients based on 3D image correlation. Physics Med. Biol. 49: 931-9, 2004.
146. \*Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, **Pollack A**. A comparison of the single and double factor high risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59:380-85, 2004.
147. \*Andrews SF, Anderson PR, Eisenberg BL, Hanlon AL, **Pollack A**. Soft tissue sarcomas treated with postoperative external beam radiotherapy with and without low-dose-rate brachytherapy. Int. J. Radiation Oncology Biol Phys. 59:475-80, 2004.
148. **Pollack A**, DeSilvio M, Khor L-Y, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach III M, Shipley WU, Hanks GE, Sandler HM. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: An analysis of RTOG 92-02. J. Clin. Oncol. 22:2133-40, 2004.
149. \*Mu Z, Hachem P, Agrawal S, **Pollack A**. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation. Prostate 60: 187-96, 2004.

150. Li JS, Freedman GM, Price R, Wang L, Anderson P, Chen L, Xiong W, Yang J, **Pollack A**, Ma C-M. Clinical Implementation of intensity-modulated tangential beam irradiation for breast cancer. *Med. Phys.* 31:1023-31, 2004.
151. \*Li R, Heydon K, Hammond ME, Grignon D, Roach M, Wolkov H, Sandler HM, Shipley WU, **Pollack A**. Ki-67 Staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: An analysis of patients in RTOG Protocol 8610. *Clin. Cancer Res.* 4118-24, 2004.
152. Buyyounouski MK, Horwitz EM, Uzzo RG, Price RA, McNeeley SW, Azizi D, Hanlon AL, Milestone BN, **Pollack A**. Radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. *Int. J. Radiat. Oncol. Biol. Phys.* 59:1383-1391, 2004.
153. Uzzo RG, Brown JG, Horwitz EM, Hanlon A, Mazzoni S, Konski A, Greenberg RE, Pollack A, Kolenko V, Watkins-Bruner D. Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer. *BTU Int.* 93:955-60, 2004.
154. Chen L, Price RA, Nguyen T-B, Wang L, Li JS, Qin L, Ding M, Palacio E, Ma C-M, **Pollack A**. Dosimetric evaluation of MRI-based treatment planning for prostate cancer. *Phys. Med. Biol.* 49:5157-70, 2004.
155. \*Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, **Pollack A**. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph-node involvement. *Int. J. Radiat. Oncol. Biol. Phys.* 61:695-701, 2005.
156. Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, **Pollack A**. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation? *Int. J. Radiat. Oncol. Biol. Phys.* 61:1003-10, 2005.
157. Watkins Bruner D, Linton S, Konski A, Uzzo RG, Greenberg RE, **Pollack A**, Gordon R, Cescon TP, Daly M, Young W, Goplerud J, Higman Tofani S, Engstrom P. Successful strategies for African American recruitment to prostate cancer research. *Int. J. Cancer Prev.* 1:295-306, 2005.
158. \*Buyyounouski MK, Hanlon AL, Horwitz EM, Uzzo RG, **Pollack A**. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. *Int. J. Radiat. Oncol. Biol. Phys.* 61:1291-8, 2005.
159. Chakravarti A, Winter K, Wu C, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, **Pollack A**, Sandler H, Shipley W. Expression of the Epidermal Growth Factor Receptor (EGFR) and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invasive bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group (RTOG). *Int. J. Radiat. Oncol. Biol. Phys.* 62:309-17, 2005.
160. Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, **Pollack A**. Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. *Int. J. Radiat. Oncol. Biol. Phys.* 62:397-405, 2005.
161. Andrews SF, Horwitz EM, Feigenberg SJ, Eisenberg DF, Hanlon AL, Uzzo RG, **Pollack A**. Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma? *Cancer* 104:299-04, 2005.
162. \*[Khor LY](#), [Desilvio M](#), [Al-Saleem T](#), [Hammond ME](#), [Grignon DJ](#), [Sause W](#), [Pilepich M](#), [Okunieff P](#), [Sandler H](#), [Pollack A](#). MDM2 as a predictor of prostate carcinoma outcome. An analysis of RTOG protocol 86-10. *Cancer* 104:962-7, 2005.

163. \*Nguyen KH, Hachem P, Khor L-Y, Salem N, Hunt K, Calkins P, **Pollack A**. Adenoviral-E2F-1 radiosensitizes p53<sup>wild-type</sup> and p53<sup>null</sup> human prostate cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 63:238-46, 2005.
164. \*Mu Z, Hachem P, **Pollack A**. Antisense Bcl-2 sensitizes prostate cancer cells to radiation. Prostate 65:331-40, 2005.
165. DF, Horwitz EM, Feigenberg SJ, Uzzo RG, **Pollack A**. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 63:1455-62, 2005.
166. Paskalev K, Feigenberg S, Jacob R, McNeeley S, Horwitz E, Price R, Ma C, **Pollack A**. Target localization for post-prostatectomy patients using CT and ultrasound image guidance. J. Appl. Clin. Med. Phys. 6:40-9, 2005.
167. **Pollack A**, Hanlon AL, Horwitz EM, Steven J. Feigenberg SJ, Konski AA, Movsas B, Greenberg RE, Uzzo RG, Ma C-MC, McNeeley SW, Buyyounouski MK, Price RA. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int. J. Radiat. Oncol. Biol. Phys. 64:518-26, 2006.
168. Abdel-Wahab M, Berkey BA, Krishan A, O'Brien T, Hammond E, Roach M, Lawton C, Pilepich M, Markoe A, **Pollack A**. Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Am. J. Clin. Oncol. 29:14-20, 2006
169. Konski A, Eisenberg D, Horwitz E, Hanlon A, **Pollack A**, Hanks GE. Does age matter in the selection of treatment for men with early-stage prostate cancer? Cancer 106:2598-602, 2006.
170. \*Khor L-Y, DeSilvio M, Li R, McDonnell TJ, Hammond ME, Sause W, Pilepich M, Okunieff P, Sandler H, **Pollack A**. Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in radiation therapy oncology group protocol 86-10. Int. J. Radiat. Oncol. Biol. Phys. 66:25-30, 2006.
171. Konski A, Watkins-Bruner D, Feigenberg S, Hanlon A, Kulkarni S, Beck JR, Horwitz EM, **Pollack A**. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 66:408-15, 2006.
172. Price RA, Hannoun-Levi J-M, Horwitz EM, Buyyounouski MK, Ruth KJ, Ma C-M, **Pollack A**. Impact of pelvic nodal irradiation with intensity-modulated radiotherapy on treatment of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 66:583-92, 2006
173. \*Alcántara P, Hanlon AL, Buyyounouski MK, Horwitz EM, **Pollack A**. PSA nadir within 12 months of prostate cancer radiotherapy predicts for metastasis and death. Cancer 109:41-7, 2006.
174. \*Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, **Pollack A**. Radiotherapy Dose and Late Failures in Prostate Cancer. Int. J. Radiat. Oncol. Biol. Phys. 67 1074-81, 2007.
175. D'Ambrosio DJ, Hanlon AL, Al-Saleem T, Feigenberg SJ, Horwitz EM, Uzzo RG, **Pollack A**, Buyyounouski MK. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 67: 1082-7, 2007.
176. \*Eade TN, Al-Saleem T, Horwitz EM, Buyyounouski MK, Chen DYT, **Pollack A**. The Role of Radiotherapy in Ductal (Endometrioid) Carcinoma of the Prostate. Cancer, 109: 2011-5, 2007.
177. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Kupelian PA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Shariat SF, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Fearn PA, Bianco FJ, Balshem A, Raysor S, Ross E, **Pollack**

- A.** Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. J. Clin. Oncol. 25: 2035-2041, 2007.
178. Chen L, Nguyen TB, Jone E, Chen Z, Luo W, Wang L, Price RA Jr, **Pollack A**, Ma CM. Magnetic resonance-based treatment planning for prostate intensity-modulated radiotherapy: creation of digital reconstructed radiographs. Int. J. Radiat. Oncol. Biol. Phys 68: 903-911, 2007.
179. \*Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, **Pollack A**. What external beam radiation dose is high enough for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 68: 682-689, 2007
180. Torres-Roca JF, DeSilvio M, Mora LB, Khor LY, Hammond E, Ahmad N, Jove R, Forman J, Lee JH, Sandler H, **Pollack A**. Activated Stat3 as a correlate of distant metastasis in prostate cancer: A secondary analysis of radiation therapy oncology group 8610. Urology 69: 505-509, 2007.
181. Crispen PL, Uzzo RG, Golovine K, Makhov P, **Pollack A**. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. Prostate: 67: 582-590, 2007
182. \*Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, **Pollack A**. Timing of biochemical failure and distant metastasis for low, intermediate, and high risk prostate cancer after radiotherapy. Cancer 110: 68-80, 2007.
183. \*Stoyanova R, Hachem P, Hensley H, Khor LY, Mu Z, Hammond MEH, Agrawal S, **Pollack A**. Antisense MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation and the combination *in vivo*. Int J Radiat Oncol Biol Phys 68:1151-1160, 2007.
184. Chakravarti A, DeSilvio M, Zhang M, Grignon D, Rosenthal S, Asbell SO, Hanks GE, Sandler HM, Khor LY, **Pollack A**, Shipley W. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. J Clin Oncol 25: 3082-3089, 2007.
185. Feigenberg SJ, Paskalev K, McNeeley S, Horwitz EM, Konski A, Wang L, Ma C, **Pollack A**. Comparing computed tomography localization with daily ultrasound during image-guided radiation therapy for the treatment of prostate cancer: a prospective evaluation. J. Appl. Clin. Med. Phys. 8:1-12, 2007.
186. Feng M, Hanlon AL, Pisansky TM, Kuban D, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, **Pollack A**, Kestin LL, Valicenti RK, DeWeese TL, Sandler HM. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 68:1417-1423, 2007.
187. Sharma NK, Li T, Chen DY, **Pollack A**, Horwitz EM, Buyyounouski MK. Intensity modulated radiation therapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Int J Radiat Oncol Biol Phys, 69(3):S10, 2007.
188. \*Khor LY, Moughan J, Al-Saleem T, Hammond MEH, Venkatesan V, Rosenthal SA, Ritter MA, Sandler HM, Hanks GE, Shipley WU, **Pollack A**. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on Radiation Therapy Oncology Group protocol 9202. Clin. Cancer Res. 13:3585-90, 2007.
189. Konski A, Speier W, Hanlon A, Beck R, **Pollack A**. Is proton beam therapy cost-effective in the treatment of adenocarcinoma of the prostate? J. Clin. Oncol. 25:3603-8, 2007.
190. Roach M 3<sup>rd</sup>, DeSilvio M, Rebbick T, Grignon D, Rotman M, Wolkov H, Fisher B, Hanks GE, Shipley WU, **Pollack A**, Sandler H, Watkins-Bruner. Racial differences in

- CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: A phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 69:79-87, 2007.
191. Khor LY, Bae K, **Pollack A**, Hammond MEH, Venkatesan V, Rosenthal SA, Ritter MA, Sandler HM, Hanks GE, Shipley WU, Dicker A. Cox-2 expression predicts prostate cancer outcome: an analysis of Radiation Therapy Oncology Group Trial 92-02. Lancet Oncol. 8:912-20, 2007.
  192. Che M, DeSilvio M, **Pollack A**, Grignon DJ, Venkatesan VM, Hanks GE, Sandler HM. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. Int. J. Radiat. Oncol. Biol. Phys. 69:1117-23, 2007.
  193. Abramowitz MC, Li T, Buyyounouski MK, Ross E, Uzzo RG, **Pollack A**, Horwitz EM. The Phoenix Definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer. 112:55-60, 2008.
  194. Buyyounouski MK, Hanlon AL, Horwitz EM, **Pollack A**. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 70:59-66, 2008.
  195. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, **Pollack A**. Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70:67-74, 2008.
  196. D'Ambrosio DJ, Ruth K, Horwitz EM, Uzzo RG, **Pollack A**, Buyyounouski MK. How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier? Int. J. Radiat. Oncol. Biol. Phys. 70:1487-91, 2008.
  197. \*Mu Z, Hachem P, Hensley H, Stoyanova R, Kwon HW, Hanlon A, Agrawal S, **Pollack A**. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation *in vitro* and *in vivo*. The Prostate 68:599-09, 2008.
  198. D'Ambrosio DJ, Ruth K, Horwitz EM, Chen DY, **Pollack A**, Buyyounouski MK. Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer? Urology 71:938-41, 2008.
  199. Eade TN, Horwitz EM, Ruth K, Buyyounouski MK, D'Ambrosio DJ, Feigenberg SJ, Chen DY, **Pollack A**. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int. J. Radiat. Oncol. Biol. Phys. 71:338-45, 2008.
  200. \*Khor LY, Bae K, Al-Saleem T, Hammond EH, Grignon DJ, Sause WT, Pilepich MV, Okunieff PP, Sandler HM, **Pollack A**. Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10. Int. J. Radiat. Oncol. Biol. Phys. 71:1309-15, 2008.
  201. \*Udayakumar TS, Hachem P, Ahmend MM, Agrawal S, **Pollack A**. Antisense MDM2 Enhances E2F1-Induced Apoptosis and the combination sensitizes androgen-dependent and androgen-independent prostate cancer cell to radiation. Mol. Cancer Res. 6:1742-54, 2008.
  202. Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Lin DW, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, Liauw SL, Kestin LL, Deweese TL, Scardino PT, Stephenson AJ, **Pollack A**. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology. 72:1298-302, 2008.

203. D'Ambrosio DJ, Li T, Horwitz EM, Chen DY, **Pollack A**, Buyyounouski MK. Does treatment duration affect outcome after radiotherapy for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 72:1402-07, 2008.
204. Diefenbach M, Mohamed NE, Horwitz E, **Pollack A**. Longitudinal associations among quality of life and its predictors in patients treated for prostate cancer: the moderating role of age. Psychol. Health Med. 13:146-61, 2008.
205. Zhang M, Ho A, Hammond EH, Suzuki Y, Scott Bermudez R, Jeffrey Lee R, Pilepich M, Shipley WU, Sandler H, Khor LY, **Pollack A**, Chakravarti A. Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610. Int. J. Radiat. Oncol. Biol. Phys. 73:1033-42, 2009.
206. \*Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond MEH, Grignon DJ, Che M, Venkatesan V, Byhardt RW, Rotman M, Hanks GE, Sandler HM, **Pollack A**. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: An analysis of RTOG 92-02. J. Clin. Oncol. 27:3177-84, 2009.
207. **Pollack A**, Bae K, Khor Li-Yan, Al-Saleem T, Hammond M, Venketesan V, Byhardt R, Asbell S, Shipley W, Sandler H. The importance of protein kinase A in prostate cancer: relationship to patient outcome in RTOG 92-02. Clin. Cancer Res. 15:5478-84, 2009.
208. Hill JW, Tansavatdi K, Lockett KL, Allen GO, Takita C, **Pollack A**, Hu JJ. Validation of the cell cycle G(2) delay assay in assessing ionizing radiation sensitivity and breast cancer risk. Cancer Manag. Res. 1:39-48, 2009.
209. Konski A, Movsas B, Konopka M, Ma C, Price R, **Pollack A**. Developing a radiation error scoring system to monitor quality control events in a radiation oncology department. J. Am. Coll. Radiol. 6:45-50, 2009.
210. Parker AS, Heckman MG, Wu KJ, Crook JE, Hilton TW, Pisansky TM, Bernard JR, Schild SE, Khor LY, Hammond EH, **Pollack A**, Buskirk SJ. Evaluation of ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 75:1364-70, 2009.
211. Li JS, Jin L, **Pollack A**, Horwitz EM, Buyyounouski MK, Price RA Jr, Ma CM. Gains from real-time tracking of prostate motion during external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 75:1613-20, 2009.
212. Hensley HH, Hannoun-Levi JM, Hachem P, Mu Z, Stoyanova R, Khor LY, Agrawal S, **Pollack A**. PKA knockdown enhances cell killing in response to radiation and androgen deprivation. Int. J. Cancer 128:962-73, 2010.
213. Chen L, Mu Z, Hachem P, Ma CM, Wallentine A, **Pollack A**. MR-guided focused ultrasound: enhancement of intratumoral uptake of [<sup>3</sup>H]-docetaxel in vivo. Phys. Med. Biol. 55:7399-410, 2010.
214. Chen L, Paskalev K, Xu X, Zhu J, Wang L, Price RA, Hu W, Feigenberg SJ, Horwitz EM, **Pollack A**, Ma CM. Rectal dose variation during the course of image-guided radiation therapy of prostate cancer. Radiother. Oncol. 95:198-202, 2010.
215. Zhang M, Coen JJ, Suzuki Y, Siedow MR, Niemierko A, Khor LY, **Pollack A**, Zhang Y, Zietman AL, Shipley WU, Chakravarti A. Survivin is a potential mediator of prostate cancer metastasis. Int. J. Radiat. Oncol. Biol. Phys. 78:1095-103, 2010.
216. Sharma NK, Li T, Chen DY, **Pollack A**, Horwitz EM, Buyyounouski MK. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 80:437-44, 2011.

217. Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, **Pollack A**. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int. J. Radiat. Oncol. Biol. Phys. 79:1310-7, 2011
218. Okera M, Bae K, Bernstein E, Cheng L, Lawton C, Wolkov H, **Pollack A**, Dicker A, Sandler H, Sweeney CJ. Evaluation of nuclear factor  $\kappa$ B and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. B.J.U. Int. 108:E51-8, 2011.
219. \*Udayakumar TS, Stoyanova R, Hachem P, Ahmed MM, **Pollack A**. Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivo. Int. J. Radiat. Oncol. Biol. Phys. 79:549-58, 2011.
220. Mu Z, Ma CM, Chen X, Cvetkovic D, **Pollack A**, Chen L. MR-guided pulsed high intensity focused ultrasound enhancement of docetaxel combined with radiotherapy for prostate cancer treatment. Phys. Med. Biol. 57:535-45, 2012.
221. Pahlajani N, Ruth KJ, Buyyounouski MK, Chen DY, Horwitz EM, Hanks GE, Price RA, **Pollack A**. Radiotherapy Doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 82:1949-56, 2012.
222. Keller LM, Buyyounouski MK, Sopka D, Ruth K, Klayton T, **Pollack A**, Watkins-Bruner D, Greenberg R, Price R, Horwitz EM. Stamp test delivers message on erectile dysfunction after high-dose intensity-modulated radiotherapy for prostate cancer. Urology 80:337-42, 2012.
223. Heckman MG, Parker AS, Wu KJ, Hilton TW, Ko SJ, Pisansky TM, Schild SE, Khor LY, Hammond EH, **Pollack A**, Buskirk SJ. Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancer. Prostate 72:1757-66, 2012.
224. Stoyanova R, Pahlajani NH, Egleston BL, Buyyounouski MK, Chen DY, Horwitz EM, **Pollack A**. The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms. Cancer 119:1080-8, 2013.
225. Ahmed AA, Egleston B, Alcantara P, Li L, **Pollack A**, Horwitz EM, Buyyounouski MK. A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraints. Int. J. Radiat. Oncol. Biol. Phys. 86:709-15, 2013.
226. Pan L, Baek S, Edmonds PR, Roach M 3rd, Wolkov H, Shah S, **Pollack A**, Hammond ME, Dicker AP. Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610. Radiation Oncol. 8:100 (Open Access), 2013.
227. Heckman MG, Tzou KS, Parker AS, Pisansky TM, Schild SE, Hilton TW, Patel VN, Pelaez L, Khor LY, Peterson JL, Daughterty LC, Vallow LA, **Pollack A**, Buskirk SJ. Lack of association between COX-2 staining level and biochemical recurrence following salvage radiation therapy for recurrent prostate. Cancer. J Radiat. Oncol., 2:309-14. 2013.
228. Verhoven B, Yan Y, Ritter M, Khor LY, Hammond E, Jones C, Amin M, Bahary JP, Zeitzer K, **Pollack A**. Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08. Int. J. Radiat. Oncol. Biol. Phys. 86:317-23, 2013.
229. **Pollack A**, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, Stoyanova R, Movsas B, Greenberg RE, Uzzo RG, Ma C, Buyyounouski MK. Randomized trial of



- hypofractionated external-beam radiotherapy for prostate cancer. J. Clin. Oncol. 31: 3860-68, 2013.
230. **Pollack A**, Dignam JJ, Diaz DA, Wu Q, Stoyanova R, Bae K, Dicker AP, Sandler H, Hanks GE, Feng FY. “A Tissue Biomarker-Based Model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG Protocol 92-02.” Clin. Cancer Res. 20:6379-88, 2014.
  231. Diaz DA, **Pollack A**, Reis IM, Mahmoud O, Gonzalgo ML, Ishkanian A, Fernandez G, Manoharan M, Abramowitz MC. Neoadjuvant Radiotherapy Improves Survival in Patients With T2b/T3 Bladder Cancer: A Population-Based Analysis. Clin. Genitourin. Cancer. 13:378-84, 2015
  232. Sandler K, Patel M, Lynne C, Parekh DJ, Punnen S, Jorda M, Casillas J, **Pollack A**, Stoyanova R. Multiparametric-MRI and Targeted Biopsies in the Management of Prostate Cancer Patients on Active Surveillance. Front. Oncol. 5:1-4, 2015.
  233. Huang KT, Stoyanova R, Walker G, Sandler K, Studenski MT, Dogan N, Al-Saleem T, Buyyounouski MK, Horwitz EM, **Pollack A**. Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled. Radiother. Oncol. 115: 101-106, 2015.
  234. T.S. Udayakumar, R. Stoyanova, M.M. Shareef, Z. Mu, S. Philip, K.L. Burnstein, **A. Pollack**. Edelfosine promotes apoptosis in androgen deprived prostate tumors by increasing ATF3 and inhibiting androgen receptor activity. Molecular Cancer Therapeutics, in press.
  235. E.L. Bossart, R. Stoyanova, K. Sandler, M. Studenski, A. Orman, M. Abramowitz, **A. Pollack**. Feasibility and Initial Dosimetric Findings for a Randomized Trial Using Dose-Painted Multiparametric Magnetic Resonance Imaging-Defined Targets In Prostate Cancer. Int. J. Radiat. Oncol. Biol. Phys., in press.
  236. O.N. Kryvenko, K. Lyapichev, F.M. Chinae, N.S. Prakash, **A. Pollack**, M.L. Gonzalgo, S. Punnen, M. Jorda. Radical prostatectomy outcome in White Hispanic/Latino men with NCCN very low-risk prostate cancer detected by template biopsy. American Journal of Surgical Pathology, in press.

## 18. Other works, publications and abstracts:

### Peer-reviewed Abstracts (\*Senior Author of Resident or Fellow Abstract):

1. Gratzner HG, **Pollack A**, Ingram DJ. Studies of DNA synthesis in single cells and chromosomes by immunological methodology. J. Cell Biol. 67:185, 1975.
2. **Pollack A**, Bagwell CB, Wetmore KE, Irvin GL, III. Radiation damage from Intranuclear <sup>3</sup>H in human lymphocytes. Fed. Proc. 38:4611, 1979.
3. Claflin AJ, **Pollack A**, Block NL, Irvin GL, III, and Malinin TI. Production of tumors with diploid and aneuploid cells by predominately diploid culture cells. Fed. Proc. 40:783, 1981.
4. Claflin AJ, **Pollack A**, Irvin GL, III, Block NL. Flow cytometric analysis of well- and poorly-differentiated rat prostate carcinomas. Fed. Proc. 40:786, 1981.
5. **Pollack A**, Prudhomme D, Irvin GL, III, Claflin AJ, Block NL. Flow cytometric analysis of RNA content per cell using Pyronin-Y and Methyl Green. VIII Conference on Analytical Cytology and Cytometry, Meeting. Cytometry 2:122, 1981.

6. **Pollack A**, Irvin GL, III, Stover BJ, Claflin AJ, Block NL. The in vivo selection of hormone-independent cells in R3327-G rat prostate tumors. Abstracts of the Meeting of the Cell Kinetics Society. Cell Tiss. Kinet. 15:673, 1982.
7. Sevin B.-U, Ramos R, **Pollack A**, Averette HE. In vivo chemosensitivity testing in patients with gynecologic malignancies and nude mouse xenografts by monitoring cell kinetic parameters and DNA distribution patterns. Gyn. Oncol. 17:269, 1984.
8. Block NL, **Pollack A**, Irvin GL, III, Malinin TI. Flow cytometric analysis of DNA content per cell in untreated human prostatic carcinomas. J. Urol. 131:159, 1984.
9. **Pollack A**, Block NL, Irvin GL, III. Early cell cycle response of R3327-G prostatic adenocarcinomas to castration or androgen supplementation. J. Urol. 131:123A, 1984.
10. Taupier MA, Prudhomme D, **Pollack A**, Block NL, Irvin GL, III. A monoclonal antibody that differentiates between colon cancer and normal mucosa. Cytometry (Suppl.1):45, 1987.
11. Wolloch E, Sevin BU, **Pollack A**, Ramos RR, Schiano M. Effects of caffeine on G2 nuclear protein levels in x-irradiated BG1 cells in vitro. Cytometry (Suppl. 2):44, 1988.
12. Komaki R, **Pollack A**, Cox JD, McMurtrey MJ, Mountain CF. Invasive thymoma: Four decades experience at MD Anderson Cancer Center. Radiology 173(P):218, 1989.
13. **Pollack A**, Ciancio G, Block NL. Flow cytometric DNA and nuclear protein analysis on paraffin-embedded tissue. Cytometry (Suppl.) 5:47, 1991.
14. **Pollack A**, El-Naggar AK, Cox JD, Ro JY, Sahin A, Komaki R. Thymoma: The prognostic significance of flow cytometric DNA analysis. Cytometry (Suppl.) 5:46, 1991.
15. **Pollack A**, Terry NH, Cao S, Milas L, Meistrich ML. Cell kinetics after x irradiation in MCK mouse mammary tumors grown in vivo. Radiology 185(P):244, 1992.
16. **Pollack A**, White RA, Cao S, Meistrich ML, Terry NHA. Calculating potential doubling time (T<sub>pot</sub>) using monoclonal antibodies specific for two halogenated thymidine analogues. Int. J. Rad. Oncol. Biol. Phys. 24:138, 1992.
17. **Pollack A**, Terry NHA, Van NT, Meistrich ML. Flow cytometric analysis of two incorporated thymidine analogues and DNA in mouse mammary tumors (MCAK) grown in vivo. Cytometry (Suppl. 6):385D, 1993.
18. **Pollack A**, Zagars GK, El-Naggar AK, Terry NHA. Relationship of DNA ploidy to prostate specific antigen doubling time after radiotherapy for adenocarcinoma of the prostate. Urology 44:711-718, 1994.
19. Hall MC, Troncoso P, **Pollack A**, Zhou HYE, Zagars GK, Chung LWK, von Eschenbach AC. Tumor angiogenesis in untreated clinically localized prostate cancer correlates with outcome following external beam radiotherapy. J. Urol. 151:289A, 1994.
20. Hall MC, Navone N, Troncoso P, Pisters L, **Pollack A**, Zagars GK, von Eschenbach AC, Conti C, Chung LWK. Frequency and characterization of abnormal p53 expression in clinically localized prostate cancer. J. Urol. 151:471A, 1994.
21. \*Cole CJ, **Pollack A**, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC. Local control of muscle-invasive bladder cancer: Preoperative radiotherapy and cystectomy versus cystectomy alone. Int. J. Radiat. Oncol. Biol. Phys. 30:200, 1995.
22. **Pollack A**, Terry NHA, Wu CS, Wise BM, White RA, Meistrich ML. Specific staining of iododeoxyuridine and bromodeoxyuridine in tumors double-labelled in vivo: A cell kinetic analysis. Cytometry (Suppl. 7): 113A, 1994.
23. White RA, **Pollack A**, Terry NHA, Wu CS, Meistrich ML: Estimation of cell cycle time and growth fraction in a murine tumor from measurements at a single time using two halogenated thymidine analogues. Cytometry (Suppl. 7):36, 1994.

24. **Pollack A**, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC. Preoperative radiotherapy for muscle-invasive bladder cancer: Long-term follow-up and prognostic factors for 338 patients. Radiology (Suppl. P) 193:254, 1994.
25. **Pollack A**, Zagars GK, Kopplin S. Radiation therapy and androgen ablation for clinically localized high risk prostate cancer. Radiology (Suppl. P) 193:229, 1994.
26. **Pollack A**, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman BH. The relationship of local control to distant metastasis in muscle-invasive bladder cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl. 1) 32:274, 1995.
27. Oas LG, Zagars GK, **Pollack A**. Radiation therapy alone is not successful as salvage treatment for locally recurrent prostate cancer after radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl. 1) 32:272, 1995.
28. \*Wu CS, **Pollack A**, Czerniak BA, Chyle V, Zagars GK, Dinney CP, Benedict WF. Prognostic value of P53 in patients with muscle-invasive bladder cancer treated with preoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl. 1) 32:273, 1995.
29. \*Chyle V, **Pollack A**, Czerniak BA, Stephens LC, Zagars GK, Terry NHA, Meyn, Jr. RE. Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl. 1) 32:273, 1995.
30. \*Lankford S, **Pollack A**, Zagars GK. PSA density as a prognostic factor in prostate cancer patients treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl. 1) 32:229, 1995.
31. **Pollack A**, Lim Joon D, Wu CS, Sikes C, Hasegawa M, White RA, Terry NHA, Zagars GK, Meistrich ML. Quiescence in R3327-G rat prostate tumors after androgen ablation. Cytometry (Suppl. 8):46, 1996.
32. \*Lim Joon D, **Pollack A**, El Naggar A, Cleary K, Wu C, Troncoso P, Terry NHA. Flow cytometric analysis of DNA, nuclear protein, and bromodeoxyuridine in formalin fixed nuclei. Cytometry (Suppl. 8):49, 1996.
33. **Pollack A**, Czerniak B, Zagars GK, Hu S-X, Wu CS, Dinney CPN, Chyle V, Benedict WF. Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 36:230, 1996.
34. Sands ME, Antolak J, **Pollack A**, Zagars GK, Rosen II. 3D-Conformal prostate radiotherapy: Minimizing the rectal dose by constrained simulated annealing. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 36:395, 1996.
35. \*Lim Joon D, Hasegawa M, Wu CS, Sikes C, Khoo VS, Zagars GK, Terry NHA, Meistrich ML, **Pollack A**. Supra-additive apoptotic response in predominantly quiescent prostate tumors when treated with androgen ablation and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 36:191, 1996.
36. \*Lankford SP, **Pollack A**, Zagars GK. Prostate specific antigen cancer volume: A significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 36:307, 1996.
37. **Pollack A**, Zagars GK. External beam radiotherapy dose-response of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 39:194, 1997.
38. \*Chaney AW, **Pollack A**, Zagars GK. Adjuvant radiotherapy for phyllodes tumor of the breast. Int. J. Radiat. Oncol. Phys. (Suppl.) 39:268, 1997.
39. \*Lankford SP, Geara FB, Zagars GK, **Pollack A**. Transrectal ultrasound staging is independent of clinical staging in predicting outcome following definitive radiotherapy for localized prostate cancer. Radiology (Suppl.) 205:170, 1997.
40. **Pollack A**. Management of regionally localized high-risk prostate cancer. Radiology (Suppl.) 205:76, 1997.

41. Meistrich ML, Terry NHA, **Pollack A**, White RA. Direct estimates of  $T_{G2+M}$ , in addition to  $T_S$  and  $T_{pot}$  from bivariate DNA-thymidine analogue analyses. Cytometry (Suppl.):97, 1998.
42. \*Colletier PJ, Tofilon PJ, Meyn RE, **Pollack A**. Adenoviral-mediated p53 transgene expression sensitizes wild-type p53 prostate cancer cells to irradiation. Radiation Research Society Program and Abstracts 131:123, 1998.
43. **Pollack A**, Ashoori F, Sikes C, Lim Joon D, von Eschenbach AC, Zagars GK, Meistrich ML. The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 42:178, 1998.
44. Kelly JF, **Pollack A**, Zagars GK. Pretreatment serum testosterone as a prognostic factor in patients with node positive prostate cancer treated with androgen ablation. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 42:306, 1998.
45. Ballo MT, Zagars GK, **Pollack A**. Desmoid tumor outcome following radiation therapy with and without surgical resection. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 42:193, 1998.
46. \*Colletier PJ, Tofilon PJ, Meyn RE, **Pollack A**. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and mutant p53 prostate cancer cells to irradiation. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 42:152, 1998.
47. Smith LG, **Pollack A**, Zagars GK. Predictors of distant metastasis 7 years after a rising PSA in prostate cancer patients treated with external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 45, (Suppl.) 3:218-219, 1999.
48. **Pollack A**, Zagars GK, Smith LG, Antolak JA, Rosen II. Preliminary results of a randomized dose escalation study comparing 70 Gy to 78 Gy for the treatment of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 45, (Suppl.) 3:146-147, 1999.
49. \*Salem N, Ashoori F, Meyn R, Meistrich ML, **Pollack A**. Adenoviral-mediated E2F-1 expression sensitizes prostate cancer cells in vitro to ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 45, (Suppl.) 3:295-296, 1999.
50. \*Cowen D, Salem N, Ashoori F, Meyn R, Meistrich ML, **Pollack A**. Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. Int. J. Radiat. Oncol. Biol. Phys. 45, (Suppl.) 3:184-185, 1999.
51. \*Storey MR, **Pollack A**, Zagars GK, Smith LG, Antolak JA, Rosen II. Complications from dose escalation in prostate cancer: Preliminary results of a randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 45, (Suppl.) 3:170-171, 1999.
52. Hanus MC, Zagars GK, Smith LG, **Pollack A**. Family history in prostate cancer: Outcome analysis of hereditary versus familial prostate cancer following definitive radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 45, (Suppl.) 3:343, 1999.
53. **Pollack A**, Salem N, Ashoori F, Hachem P, Sangha M, von Eschenbach AC, Meistrich ML. Lack of prostate cancer radiosensitization by androgen deprivation. Int. J. Radiat. Oncol. Biol. Phys. 48, (Suppl.) 3:274, 2000.
54. Michalski JM, Winter K, Purdy JA, Wilder R, Perez CA, Roach M, Parliament M, **Pollack A**, Markoe A, Harms WB, Sandler H, Cox JD. Update of toxicity following 3D radiation therapy for prostate cancer on RTOG 9406. Int. J. Radiat. Oncol. Biol. Phys. 48, (Suppl.) 3:228, 2000.
55. Zagars G, **Pollack A**, von Eschenbach A. Addition of radiotherapy to androgen ablation improves outcome for node-positive prostate cancer. Radiother. Oncol. 56, (Suppl.) 1:127-128, 2000.
56. McDonnell TJ, Cowen D, Troncoso P, Zagars GK, von Eschenbach AC, Meistrich ML, **Pollack A**. Molecular markers of patient outcome in prostate cancer treated with

- radiotherapy: Ki-67, Bcl-2, Bax and Bcl-x. Int. J. Radiat. Oncol. Biol. Phys. 51, (Suppl.) 1:112, 2001.
57. Ryu J, Winter K, Michalski J, Purdy J, Markoe A, Earle J, Perez C, Roach M, Sandler H, Cox J, **Pollack A**. Preliminary report of toxicity following 3D conformal radiation therapy (3DCRT) for prostate cancer on 3DOG/RTOG 9406, Level III (79.2 Gy) Int. J. Radiat. Oncol. Biol. Phys. 51(3), (Suppl.) 1:136, 2001.
  58. **Pollack A**, Zagars GK, Antolak JA, Kuban DA, VonEschenbach AC, Rosen II. Relationship of prostate biopsy status to radiotherapy dose, PSA nadir level and outcome in participants of a randomized dose escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 51, (Suppl.) 1:142, 2001.
  59. \*Chandra A, Dong L, Huang E, Kuban DA, O’Neill LJ, Rosen A, **Pollack A**. Evaluation of ultrasound-based daily prostate localization during IMRT for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 51, (Suppl.) 1:167, 2001.
  60. \*Huang E, Dong L, Chandra A, Kuban D, Rosen II, **Pollack A**. Intrafraction prostate motion during IMRT for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 51, (Suppl.) 1:212, 2001.
  61. \*Little DJ, Kuban DA, **Pollack A**. Results of a quality of life questionnaire two and three years after external beam radiotherapy for prostate cancer in a randomized dose escalation study. Int. J. Radiat. Oncol. Biol. Phys. 51(3), (Suppl.) 1:300, 2001.
  62. Rosser CJ, Chichakli R, Levy LB, Kuban DA, **Pollack A**, Smith L, Pisters L. Assessment of biochemical disease free progression in men with prostate cancer younger than 60 years of age: MD Anderson experience. Int. J. Radiat. Oncol. Biol. Phys. 51(3), (Suppl.) 1:303, 2001.
  63. Taylor NA, Kelly JF, Kuban DA, Babaian RJ, Pisters LL, **Pollack A**. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 51(3), (Suppl.) 1:317, 2001.
  64. Dong L, O’Daniel JC, Smith LG, Kuban DA, Bounds SL, Rosen II, **Pollack A**. Comparison of 3D conformal and intensity-modulated radiation therapy for early-stage prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 51(3), (Suppl.) 1:320, 2001.
  65. Dsouza WD, Palmer MB, Lee HK, Smith LG, **Pollack A**. Is nomogram-based intraoperative overplanning of I-125 prostate implants necessary? Int. J. Radiat. Oncol. Biol. Phys. 51(3), (Suppl.) 1:392, 2001.
  66. **Pollack A**, Hanlon AL, Horwitz EM, Hanks GE. Prostate cancer dose response to conformal radiotherapy. J. Urol. (Suppl.) 167:391, 2002.
  67. Rosser CJ, Kuban DA, Levy LB, Chichakli R, **Pollack A**, Lee A, Pisters LL. The PSA “bounce” phenomena after external beam radiation for clinically localized prostate cancer. J. Urol. (Suppl.) 167:391, 2002.
  68. Chakravarti A, Heydon K, Wu C-L, Hammond E, **Pollack A**, Roach M, Wolkov H, Okunieff P, Komaki R, Fontanesi J, Abrams R, Pilepich M, Shipley W. Loss of P16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from RTOG 86-10. J. Urol. (Suppl.) 167:337, 2002.
  69. **Pollack A**, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Kuban DA, Huang E. Prostate cancer radiation dose response: Final planned analysis of a phase III randomized trial. ASCO Program Proceedings (1 of 2) 21:176a, 2002.
  70. **Pollack A**, Hanlon AL, Movsas B, Hanks GE, Horwitz EM. Correlates of distant metastasis and death in prostate cancer patients treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 54:11, 2002.
  71. Horwitz EM, Uzzo RG, Hanlon AL, Greenberg RE, Hanks GE, **Pollack A**. Does backdating change outcome when the ASTRO definition of biochemical control is used

- in patients with clinically localized prostate cancer treated with 3D conformal radiation therapy alone? Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 54:11, 2002.
72. Kuban DA, **Pollack A**, Huang E, Levy L, Dong L, Starkschall G, Rosen I. The hazards of dose escalation in prostate cancer radiation. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 54:107, 2002.
  73. Huang EH, **Pollack A**, Levy L, Starkschall G, Dong L, Rosen I, Kuban D. Late rectal toxicity: Dose-volume effects of conformal radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.): 54:110, 2002.
  74. \*Nguyen KH, Horwitz EM, Hanlon AL, Uzzo R, **Pollack A**. Does short-term androgen deprivation substitute for radiation dose in the treatment of high risk prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 54:135, 2002.
  75. Hanlon AL, Horwitz EM, Hanks GE, **Pollack A**. Short term androgen deprivation and PSA doubling time: Their relationship to one another and to disease progression following radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 54:136, 2002.
  76. \*Kaminski JM, Hanlon AL, Joon DL, Meistrich M, **Pollack A**. The effect of sequencing of androgen ablation and radiation on prostate cancer growth. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 54:190, 2002.
  77. Mu A, Hachem P, Agrawal S, **Pollack A**. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 54:191, 2002.
  78. Moore DF, Hanlon A, Hanks GE, **Pollack A**. Model-based prediction of biochemical failure in prostate cancer patients following radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 54:260, 2002.
  79. Price RA, **Pollack A**, Horwitz E, Movsas B, McNeeley S, Chen L, D'Emilia, Ma C. Improved target coverage and rectal sparing for treatment of prostate cancer using IMRT vs. 3D CRT. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 54:261, 2002.
  80. Buyyounouski MK, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE, **Pollack A**. The use of prostate biopsy laterality results in localized prostate cancer does not predict for 7-yr b-NED outcome. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 54:264, 2002.
  81. Chism DB, Hanlon AL, Troncoso P, Horwitz EM, **Pollack A**. The impact on outcome of the Gleason score shift. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 54:265, 2002.
  82. Kramer NM, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE, **Pollack A**. Outcome analysis of prostate cancer patients treated with observation. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 54:273, 2002.
  83. \*Diratzouian H, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE, **Pollack A**. Radiation dose requirements for favorable risk prostate cancer subgroups using recursive partitioning. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 54:277, 2002.
  84. Chen L, Li J, Mah D, Ma C, Price R, Wang L, McNeeley S, Ding M, Freedman G, Movsas B, **Pollack A**. Monte Carlo verification of MR-based treatment planning for intensity modulated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 54:329, 2002.
  85. Andrews S, Anderson PR, Hanlon AL, **Pollack A**. Soft tissue sarcomas treated with external beam radiation therapy with and without the addition of low dose rate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 54:340, 2002.
  86. \*Buyyounouski MK, Hanlon AL, **Pollack A**. The temporal kinetics of PSA after 3D-conformal radiotherapy with androgen deprivation. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 57:147, 2003.

87. \*Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, **Pollack A**. Role of prostate dose escalation in patients with >15% risk of pelvic lymph-node involvement. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 57:150, 2003.
88. Feigenberg SJ, Hanlon AL, Horwitz EM, **Pollack A**. Androgen deprivation increases late morbidity in prostate cancer patients treated with 3D conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 57:176, 2003.
89. **Pollack A**, DeSilvio M, Khor L, Li R, Al-Saleem T, Hammond M, Venkatesan V, Byhardt R, Hanks GE, Roach M, Shipley WU, Sandler HM. Ki-67 Staining is a strong predictor of patient outcome for prostate cancer patients treated with androgen deprivation plus radiotherapy: An analysis of RTOG 92-02. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 57:200, 2003.
90. Hughes, LA, Heydon K, Edmonds P, Roach M, Wolkov H, Shah S, **Pollack A**, Hammond M, Dicker AP. Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer (LAPC): Secondary analysis of Radiation Therapy Oncology Group (RTOG) 8610. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 57:201, 2003.
91. \*Mu Z, Hachem P, Agrawal S, **Pollack A**. Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 57:256, 2003.
92. \*Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, **Pollack A**. A comparison of the single vs. double high-risk factor stratification systems for prostate cancer treated with brachytherapy without androgen deprivation. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 57:270, 2003.
93. Chen, L, Price RA, Li J, Wang L, Qin L, Ding M, Ma C, **Pollack A**. Clinical implementation of MRI simulation for IMRT of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 57:338, 2003.
94. Hanlon AL, Horwitz EM, Hanks, GE, **Pollack A**. Post-radiotherapy PSA nadir remains highly predictive of outcome in men who are biochemically free of disease at 1.5 Years post-treatment. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 57:397, 2003.
95. \*Nguyen KH, Freedman GM, Hanlon AL, Nicolaou N, Anderson PR, **Pollack A**. Smoking cessation confers survival advantage for breast cancer patients treated with conservative surgery and radiation. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 57:358-359, 2003.
96. Uzzo RG, Horwitz EM, **Pollack A**, Greenberg RE, Kolenko VM. Zinc Inhibits NFKB Activation and sensitizes prostate cancer cells to apoptotic death via cytotoxic agents. J. Urol. (Suppl.) 169:155, 2003.
97. Rosser CJ, Levy LB, Kuban, DA, Chichakli R, **Pollack, A**, Lee A, Pisters LL. Hazard rates of disease progression after external-beam radiotherapy for clinically localized carcinoma of the prostate. J. Urol. (Suppl.) 169:180, 2003.
98. Uzzo RG, Horwitz EM, Hanlon AL, Hanks GE, Greenberg RE, **Pollack A**. Impact of backdating on biochemical NED rates using the ASTRO definition following 3-D conformal radiation for prostate cancer. J. Urol. (Suppl.) 169:437, 2003.
99. **Pollack A**, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG. Prostate cancer treated with radiotherapy with or without androgen deprivation: The importance of the PSA nadir within 12 months. ASCO Program Proceedings 23:399s, 2004.
100. **Pollack A**, DeSilvio M, Khor L-Y, Al-Saleem T, Hammond EH, Li R, Roach M, Rosenthal SA, Movsas B, Shipley WU, Hanks GE, Sandler HM. Recursive partitioning analysis of predictors of distant metastasis for men with prostate cancer treated with radiotherapy and androgen deprivation on RTOG 9202: The impact of Ki-67. J. Urol. (Suppl.) 171:383, 2004.

101. Diefenbach MA, Uzzo RG, Horwitz E, Greenberg RE, **Pollack A**, Raysor S, Dorsey J. Quality of life among men with localized prostate cancer: A two-year longitudinal assessment. J. Urol. (Suppl.) 171:281, 2004.
102. Konski AA, Watkins-Bruner D, Feigenberg S, Hanlon A, Kulkarni S, Beck J, **Pollack A**. Intensity Modulated Radiation Therapy (IMRT) is a cost-effective treatment for intermediate risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 60:144, 2004.
103. \*Mu Z, Hachem P, **Pollack A**. Antisense to Bcl-2 (Genasense™) Sensitizes prostate cancer cells to radiation. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 60:176, 2004.
104. **Pollack A**, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton C, Michalski JM, Zelefsky MJ, Kupelian PA, Kestin LL, Valicenti RK, DeWeese TL. A multi-institutional analysis of adjuvant and salvage radiotherapy after radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 60:186, 2004.
105. Hanlon AL, Horwitz EM, Feigenberg SJ, **Pollack A**. Identification of groups at risk for distant metastasis and death in men with a rising PSA after radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 60:233, 2004
106. Feigenberg S, Hanlon AL, Horwitz EM, Uzzo RG, **Pollack A**. Post-treatment PSA values within 6 months of 3D conformal radiotherapy for prostate cancer predict for distant metastases. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 60:234, 2004.
107. Schultheiss TE, Movsas B, Jacob R, McNeeley S, Hanks GE, **Pollack A**. Dose-volume histogram analysis does not completely predict the incidence of late effects of radiation in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 60:268, 2004.
108. Abdel-Wahab M, Berkey B, Krishan A, O'Brien T, Hammond E, Roach M, Lawton C, Pilepich M, Markoe A, **Pollack A**. Influence of number of CAG repeats on local control in the RTOG 86-10 Protocol. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 60:326, 2004.
109. \*Buyyounouski M, Hanlon AL, Horwitz EM, Feigenberg SJ, Al-Saleem TI, **Pollack A**. Pretreatment risk stratification of prostate cancer with percent positive prostate biopsy tissue obviates the need for clinical staging and identifies high grade disease suitable for treatment without androgen deprivation. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 60:443, 2004.
110. \*Andrews SF, Horwitz EM, Feigenberg SJ, Eisenberg DF, Hanlon AL, Uzzo RG, **Pollack A**. Does a delay in initiation of external beam radiation therapy after tissue diagnosis effect outcome for men with prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 60:440, 2004.
111. \*Nguyen KH, Eisenberg DF, Hanlon AL, Horwitz EM, **Pollack A**. NSAID use confers a survival advantage for prostate cancer patients treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 60:445, 2004.
112. Hayes SB, Hanlon AL, Horwitz EM, **Pollack A**, Uzzo RG, Feigenberg SJ. Are there any prostate cancer patients without high risk features who need long term androgen deprivation with external beam radiation therapy? A recursive partitioning analysis. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 60:455, 2004.
113. \*Hannoun-Levi J, Hachem P, Mu Z, Agrawal S, **Pollack A**. Protein Kinase A R1 $\alpha$  antisense sensitization of radiation and androgen deprivation. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 60:462, 2004.
114. \*Khor L, DeSilvio ML, Al-Saleem T, Hammond ME, Sause WT, Pilepich MV, Okunieff P, Sandler HM, **Pollack A**. MDM2 as a predictor of prostate cancer outcome: An analysis of RTOG 8610. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 60:472, 2004.
115. \*Jacob R, Feigenberg S, Eisenberg D, Hanlon A, Horwitz E, **Pollack A**. Is there a role for digital rectal examination in the follow-up of patients with prostate cancer treated



- with radiotherapy in the PSA era? Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 60:476, 2004.
116. Price RA, Hannoun-Levi J, Ma CC, **Pollack A**. Pelvic lymphatic coverage in the treatment of prostate cancer with Intensity Modulated Radiation Therapy: A feasibility study. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 60:635, 2004.
  117. Konski AA, Feigenberg S, Raysor S, Eisenberg D, Mirchandani I, Uzzo RG, Greenberg R, Horwitz E, **Pollack A**, Hanks G, Watkins-Bruner D. Twenty-five percent positive biopsy rate in a high risk prostate cancer screening program with a PSA  $\leq 2.5$  ng/ml. ASCO Program Proceedings (1 of 2) 23:392s, 2005.
  118. Torres-Roca JF, DeSilvio M, Mora-Diaz LB, Hammond E, Ahmad N, Jove R, Forman J, Lee RJ, Sandler H, **Pollack A**. Stat3 as a correlate of distant metastasis in RTOG 86-10. ASCO Program Proceedings (1 of 2) 23:416s, 2005.
  119. **Pollack A**, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton C, Michalski JM, Zelefsky MJ, Kupelian PA, Kestin LL, Valicenti RK, DeWeese TL. Which definition of biochemical failure after postoperative radiotherapy predicts best for clinical failure? Program Abstracts AUA Annual Meeting, J.Urol. 173S:308-309, 2005.
  120. **Pollack A**, DeSilvio M, Khor LY, Hammond ME, Al-Saleem T, Grignon D, Che M, Varagur V, Byhardt R, Rotman M, Hanks GE, Sandler H. MDM2 expression is independent of P53 and Ki-67 in predicting prostate cancer outcome: an analysis of RTOG 92-02. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 63:S17, 2005.
  121. Chakravarti A, Desilvio M, Zhang M, Grignon D, Rosenthal S, Asbell S, Hanks G, Sandler H, **Pollack A**, Zhai G, Shipley W. The prognostic value of p16 expression in locally advanced prostate cancer: A study based on RTOG 92-02. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 63:S17, 2005.
  122. Zhang M, Ho A, Hammond E, Roach M, Sause W, Pilepich M, Shipley W, Sandler H, **Pollack A**, Chakravarti A. The prognostic value of survivin in locally advanced prostate cancer: A study based on RTOG 8610. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 63:S18, 2005.
  123. Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton C, Michalski JM, Zelefsky MJ, Kupelian PA, Kestin LL, DeWeese TL, **Pollack A**. A Multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3/4N0 prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 63:S123, 2005.
  124. Feng M, Hanlon AL, Pisansky TM, Kuban DA, Catton C, Michalski JM, Zelefsky MJ, Kupelian PA, **Pollack A**, Kestin LL, Valicenti RK, DeWeese TL. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 63:S127, 2005.
  125. Buyyounouski MK, Hanlon AL, Horwitz EM, **Pollack A**. The percentage of positive cores is not an appropriate risk factor for prostate radiotherapy to  $\geq 72$  Gy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 63:200, 2005.
  126. \*Alcantara P, Schultheiss TE, Ruth K, Shammo G, McNeeley S, Horwitz E, **Pollack A**. Dose-volume determinants of late genitourinary toxicity after external beam radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 63:S294, 2005.
  127. Hanlon AL, Horwitz EM, Feigenberg SJ, **Pollack A**. Predictors of hormone refractory disease in men treated with salvage androgen deprivation following definitive radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 63:S296, 2005.
  128. D'Ambrosio DJ, Buyyounouski MK, Horwitz EM, Feigenberg SJ, Ruth K, **Pollack A**. Men with intermediate risk prostate cancer with a history of transurethral resection of prostate (TURP) have a higher risk of biochemical failure. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 63:S311, 2005.

129. Zhai G, Ho A, Hammond E, Fontanesi J, Rotman M, Pilepich M, Shipley W, Sandler H, **Pollack A**, Zhang M. Phospho-AKT expression and prognosis of locally advanced prostate cancer: A study based on RTOG 8610. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 63:S319, 2005.
130. Andrews SF, Horwitz EM, Feigenberg SJ, Eisenberg DF, Uzzo RG, **Pollack A**. Does a delay in low dose rate (LDR) brachytherapy after tissue diagnosis affect outcome for men with low risk prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 63:S323, 2005.
131. Nguyen KH, Horwitz E, Eisenberg D, Hanlon A, Feigenberg A, **Pollack A**. Does hyperinsulinemia in type-II diabetes mellitus influence disease presentation and long-term treatment outcomes of localized prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 63:S330, 2005.
132. Chen L, Paskalev K, Zhu J, Xu X, Wang L, Price RA, Horwitz E, Feigenberg S, Ma CC, **Pollack A**. Image guided radiation therapy for prostate IMRT: rectum volume changes and dosimetric considerations. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 63:S549, 2005.
133. Golovine K, Markov P, Greenberg RE, Horwitz EM, **Pollack A**, Kolenko VM, Uzzo RG. Inhibition of NF-kB in prostate cancer cells by vitamin E succinate (VES) decreases metastatic potential by altering expression of pro-metastatic molecules and decreasing cell invasiveness and adhesion. J. Urol. 175:261, 2006.
134. Stephenson AJ, **Pollack A**, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Kupelian PA, Anscher MS, Michalski JM, Sandler HM, Zelefsky MJ, Forman JD, Lin DW, Kestin LL, Pistenmaa DA, Catton CN, Dewese TL, Valicenti RK, Kuban DA, Bianco FJ, Fearn PA. A nomogram to predict the outcome of salvage radiotherapy (RT) for biochemical recurrence (BCR) following radical prostatectomy (RP). J. Urol. 175:384, 2006.
135. Stephenson AJ, **Pollack A**, Kattan MW, Scardino PT. Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. ASCO Program Proceedings (1 of 2) 24:220s, 2006.
136. Abramowitz MD, Li T, Buyyounouski MK, Ross E, Uzzo RG, **Pollack A**, Horwitz EM. The nadir+2 definition of biochemical failure predicts for overall survival. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S207, 2006.
137. Buyyounouski MK, Hanlon AL, Horwitz EM, **Pollack A**. The prostate specific antigen velocity is unaltered by radiotherapy alone when 2 ng/mL per year or greater: distant metastasis are the cause. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S206, 2006.
138. D'Ambrosio DJ, Ruth K, Buyyounouski MK, Horwitz EM, Uzzo RG, **Pollack A**. Prostate specific antigen kinetics in men treated with radiotherapy and androgen deprivation. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S334, 2006.
139. Eade TN, Ruth K, D'Ambrosio DJ, Feigenberg SJ, Buyyounouski MK, Uzzo RG, **Pollack A**, Horwitz EM. Comparison of outcomes in low risk prostate cancer: I-125 seed brachytherapy vs. intensity modulated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S60, 2006.
140. Hachem P, Bae K, Khor L, Hammond ME, Al-Saleem T, Li L, Hanks GE, Sandler H, **Pollack A**. Prostate tumor biomarker stability in archival tissue from men treated with radiotherapy: an analysis of RTOG 92-02 and Fox Chase Cancer Center randomized trials. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S365, 2006.
141. Hanlon AL, Horwitz EM, Buyyounouski MD, **Pollack A**. Adjusted radiotherapy dose response curves following treated for prostate cancer: biochemical failure and distant metastasis. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S346, 2006.

142. \*Khor LY, Bae K, Hammond ME, **Pollack A**, Venkatesan V, Rosenthal SA, Sandler H, Hanks GE, Shipley WU, Dicker AP. Cox-2 overexpression predicts prostate cancer outcome: an analysis of RTOG 92-02. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S202, 2006.
143. \*Kirichenko A, Ruth K, Horwitz E, Buyyounouski M, Feigenberg S, Chen D, **Pollack A**. Intensity modulated radiotherapy for prostate cancer: preliminary results on treatment toxicity compared to 3D conformal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S326, 2006.
144. Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, **Pollack A**. Increasing radiotherapy dose for prostate cancer reduces a late wave of distant metastasis. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S9, 2006.
145. \*Mu Z, Hachem P, Hensley H, Stoyanova R, Hanlon AL, Agrawal S, **Pollack A**. Antisense MDM2 oligonucleotides sensitize androgen-insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S203, 2006.
146. \*Pahlajani NH, Ruth K, Horwitz EM, Buyyounouski MK, Chen DY, **Pollack A**. Smoking and its relationship to GU and GI toxicity in prostate cancer patients treated with radiation. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S317, 2006.
147. Paskalev K, Feigenberg S, McNeeley S, Horwitz EM, Price R, Konski A, Buyyounouski M, Ma C, **Pollack A**. CT-based daily localization of prostate patients: anatomy vs. implanted markers, Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S621\*, 2006.
148. **Pollack A**, Moughan J, Khor L, Al-Saleem T, Hammond ME, Venkatesan V, Rosenthal SA, Hanks GE, Shipley W, Sandler H. Bcl-2 and Bax predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on RTOG 92-02. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S201, 2006.
149. \*Udayakumar TS, Hachem P, Agrawal S, **Pollack A**. Adenoviral E2F1 and antisense MDM2 sensitize prostate cancer cells to androgen deprivation and radiation. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S313, 2006.
150. Kuban D, Tucker S, Dong L, Huang E, Lee A, Cheung R, Starkschall G, **Pollack A**. Long-term results of a randomized dose escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S8, 2006.
151. Stoyanova R, Hachem P, Hensley HH, Kwon H, **Pollack A**. Antisense MDM2 sensitizes prostate tumors to radiation therapy and androgen deprivation *in vivo*. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S202, 2006.
152. Hensley HH, Hachem P, Stoyanova R, Kwon H, **Pollack A**. Protein kinase a antisense induces apoptosis and sensitizes prostate tumors to androgen deprivation. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S319, 2006.
153. Zhang M, Ho A, Hammond E, Sause W, Pilepich M, Shipley W, Sandler H, Khor L, **Pollack A**, Chakravarti A.. The prognostic value of survivin in locally advanced prostate cancer: a study based on RTOG 8610. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S326, 2006.
154. \*Sharma NK, Ruth K, Horwitz E, Buyyounouski M, **Pollack A**. Statin use prior to radiation therapy for prostate cancer does not improve outcome: The Fox Chase Experience. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 66:S366, 2006.
155. Buyyounouski MK, Li T, Watkins-Bruner D, Horwitz EM, **Pollack A**. A comparison of sexual function following radiotherapy for prostate cancer: Results of a prospective, randomized trial of hypofractionated intensity modulated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 69:S7, 2007.

156. Sharma NK, Li T, Horwitz EM, **Pollack A**, Buyyounouski M. Intensity-modulated radiation therapy reduces gastrointestinal morbidity in patients treated with androgen deprivation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 69:S10, 2007.
157. Horwitz EM, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton C, Michalski JM, Stephenson A, **Pollack A**. The Phoenix Definition of biochemical failure correlates with clinical failure for men treated with adjuvant and salvage post-prostatectomy radiation: Results of the multi-institutional pooled analysis. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 69:S173, 2007.
158. D'Ambrosio D, Li T, Horwitz EM, Chen D, **Pollack A**, Buyyounouski MK. Does total treatment duration affect outcome in prostate cancer treated with radiotherapy? Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 69:S176, 2007.
159. Li J., **Pollack A.**, Horwitz E., Buyyounouski M, Price R, Ma C. Clinical experience on localization and real-time tracking of the prostate during external radiotherapy using Calypso® 4D localization system Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 69:S189, 2007.
160. \*Morgan P.B., Ruth K., Horwitz E.M., Buyyounouski M.K., Uzzo R.G., **Pollack A**. A matched pair comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy for prostate cancer: toxicity and outcomes. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 69:S319, 2007.
161. \*Padovani L, Mu Z, Mercier C, Hachem P, **Pollack A**. Edelfosine: A promising new drug for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 69:S328, 2007.
162. Chen Y., Paskalev K., Horwitz E., Price R., Buyyounouski M., Ma C., **Pollack A**. Effect of target smoothness on treatment planning for prostate IMRT. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 69:S649, 2007.
163. **Pollack A.**, Bae K., Khor L., Hammond E.H., Chakravarti A., Dicker A., Brereton H.D., Byhardt R., Venketesan V., Sandler H. A model for distant metastasis incorporating tissue biomarkers from prostate cancer patients in radiation therapy oncology group (RTOG) 92-02. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 72 :S58, 2008.
164. Khor L., Bae K., Al-Saleem T., Hammond E.H., Venketesan V., Byhardt R., Asbell S., Shipley W., Sandler H., **Pollack A**. Protein Kinase A RI- $\alpha$  over expression is associated with prostate cancer outcome in men treated with androgen deprivation and radiotherapy: A secondary analysis of RTOG 92-02. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 72:S54-S55, 2008.
165. Pahlajani N.H., Egleston B.L., Buyyounouski M.K., Chen D.Y.T., Horwitz E., **Pollack A**. Estimating gains in biochemical outcome from various durations of androgen deprivation in patients treated with dose escalated radiotherapy for prostate cancer using two nomograms. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 72:S54, 2008.
166. Buskirk S.J., Parker A., Heckman M., Crook J., Pisansky T., Ko S., Schild S., Khor L., Hammond E., **Pollack A**. Evaluation of Ki-67 expression as an independent biomarker of biochemical failure following salvage radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 72: S55, 2008.
167. **Pollack A.**, Bae K., Khor L., Hammond E.H., Chakravarti A., Dicker A., Brereton H.D., Byhardt R., Venketesan V., Sandler H.. A model for distant metastasis incorporating tissue biomarkers from prostate cancer patients in radiation Therapy Oncology Group (RTOG) 92-02. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 72:S58, 2008.
168. Silverman J.S., Ruth K., Horwitz E.M., **Pollack A.**, Chen D.Y.T., Buyyounouski M.K. Radiation therapy for high risk prostate cancer: Do patients 70 years or older

- benefit from combined androgen deprivation therapy? Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 72:S75-S76, 2008.
169. Udayakumar T.S., Hachem P., Stoyanova R., Ahmed M., **Pollack A.** Adenoviral-E2F1 in combination with androgen deprivation and radiation inhibit prostate tumor growth in nude mice. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 72:S76, 2008.
  170. Horwitz E.M., Ruth K., Uzzo R.G., Buyyounouski M.K., Wong Y., Chen D.Y.T., **Pollack A.** PSA doubling time predicts for the development of distant metastases for patients who fail 3DCRT or IMRT using the Phoenix definition. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 72:S135-S136, 2008.
  171. Li J., Jin L., Horwitz E., Buyyounouski M., **Pollack A.** Johnston S., Price Jr. R., Ma C. Gains from real-time prostate motion monitoring during external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 72: S287-S288, 2008.
  172. Ma C., Chi Z., Xu Q., Chen L., Paskalev K., Buyyounouski M., Horwitz E., **Pollack A.** Image guided adaptive radiotherapy of prostate cancer: A retrospective study. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 72:S306, 2008.
  173. Mu Z., Hachem P., Cheung L., Stoyanova R., **Pollack A.** Therapeutic effects of edelfosine with androgen deprivation in androgen sensitive prostate cancer cells in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 72:S313-S314, 2008.
  174. Buyyounouski M.K., Li T., Al-Saleem T., Horwitz E., Konski A., Feigenberg S., Uzzo R., Greenberg R., **Pollack A.** Predicting local persistence of intermediate and high-risk prostate cancer using percentage of adenocarcinoma in pretreatment biopsy tissue. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 72:S321-S322, 2008.
  175. Chen L., Mu Z., Hachem P., Konski A., Freedman G., Ma C., **Pollack A.** MR guided focused ultrasound for cancer therapy: enhancement of drug delivery in prostate tumor *In Vivo*. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 72:S548-S549, 2008.
  176. **Pollack A.**, Li T., Buyyounouski M., Horwitz R., Price R., Feigenberg S., Konski A., Greenberg R., Uzzo R., Ma C. Hypofractionation for prostate cancer: interim results of a randomized trial. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 75:S81-S82, 2009.
  177. Hobeika GA., Walker G., Patton B., Nguyen J., Arnold D., **Pollack A.**, Vampola S., Takita C., Wolfson A., Hatoum G, et al. Definitive chemoradiotherapy for locally advanced oropharyngeal cancer: A comparison of 3D-CRT vs. IMRT. Int. J. Radiat. Oncol. Biol. Phys. (Suppl) 75:S411-S412, 2009.
  178. Abdel-Wahab M., Schally A.V., Szalontay L., Rick F.G., Varga J.L., Shi Y.F., Zarandi M., **Pollack A.**, Duncan R. Radioprotection by antagonists of growth hormone releasing hormone during whole body radiation is dependent on the radiation dose. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 75:S552-S553, 2009.
  179. Lally B.E., Koumenis C., Mu Z., Testa JR., **Pollack A.** Preclinical studies of a novel small molecule radiosensitizer of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 75:S561-S561, 2009.
  180. Chen L., Mu Z., Hachem P., Ma C., **Pollack A.** Enhancement of 3H-Docetaxel delivery on prostate tumor *In Vivo* using MR-guided focused ultrasound. Int. J. Radiat. Oncol. Biol. Phys. 75 (Suppl.):S563-S563, 2009.
  181. Wang K., Wu X., Bossart E., Both J.A., Stoyanova R., **Pollack A.** The uncertainties in target localization for prostate and prostate-bed radiotherapy with Calypso 4D. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 75:S594-S594, 2009.
  182. Wu X., Ahmed M.M., **Pollack A.** On modern technical approaches of 3D high-dose lattice radiotherapy (LRT). Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 75:S723-S723, 2009.
  183. Chen L., Mu Z., Hachem P., Ma C.M., **Pollack A.** Enhancement of drug delivery in prostate tumor in vivo using MR Guided Focused Ultrasound (MRgHIFU). Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 75:S723-S723, 2009.

- Proc. 25:341-344, 2009
184. Turaka A., Zhu F., Buyyounouski M.K., Horwitz E.M., Watkins-Bruner D., Konski A.A., **Pollack A.** Conventional versus Hypofractionated IMRT: Results of late GI and GU toxicity and quality of life from a Phase III Trial. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 78:S67-S67, 2010
  185. Diaz D.A., Lally B.E., **Pollack A.** A SEER survival analysis of high grade prostate cancer: Surgery vs. Radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 78:S150-S150, 2010.
  186. Takita C., Ferrell A., Walker G., Wright J.L., Gunaseelan V., Wahab M.A., Wolfson A.H., Markoe A.M., Mahmoud O., **Pollack A.** Breast cancer subtype and locoregional outcomes in Locally Advanced Breast Cancer (LABC). Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 78:S212-S212, 2010.
  187. Stoyanova R., Ackerstaff E., Cho H., Koutcher J.A., **Pollack A.** DCE-MRI for delineation of hypoxic regions in prostate tumors. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 78:S337, 2010.
  188. Keller L.M., Ruth K., Horwitz E.M., **Pollack A.**, Watkins-Bruner D., Konski A., Greenberg R., Price R., Buyyounouski M.K. The stamp test delivers the message on erectile dysfunction following high dose IMRT. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 78:S596-S597, 2010.
  189. **Pollack A.**, Udayakumar T.S., Shareef M.M., Ahmed M.M. Truncated E2F1 radiosensitizes prostate cancer cells by inhibiting the E3 Ubiquitin Ligase SKP2. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 78:S645-S646, 2010.
  190. Huang K.T., Wu X., **Pollack A.** A new approach for tracking central and peripheral lung tumors without fiducials. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 78:S687, 2010.
  191. Wu X., Bossart E., Wang K., **Pollack A.** Multi-fold radiotherapy technique. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 78:S813, 2010.
  192. **Pollack A.**, Walker G., Buyyounouski M., Horwitz E., Price R., Feigenberg S., Konski A., Stoyanova R., Ma C. Five year results of a randomized External Beam Radiotherapy Hypofractionation Trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 81:S1, 2011.
  193. Ritter M.A., Yan Y., Verhoven B., Khor L., Hammond E., Jones C.U., Amin M.B., Bahary J., Zeitzer K.L., **Pollack A.** Ki-67 staining is a strong predictor of patient outcomes for prostate cancer patients treated on RTOG 94-08. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 81:S11-S12, 2011.
  194. Bossart E.L., Stoyanova R., Garugu R., Tubin S., **Pollack A.**, Wu X. Escalated dose painting of DCE-MRI defined regions of high tumor burden in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 81:S29-S30, 2011.
  195. Hu J.J., Stoyanova R., Deasy J.O., Chung R., Martin E., Buyyounouski M.K., Allen G.O., **Pollack A.** Genetic polymorphisms of DNA repair and inflammatory responses as determinants of late toxicity in prostate cancer patients who received radiotherapy in a randomized trial. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 81:S109-S110, 2011.
  196. Oh J., Deasy J., Stoyanova R., Saleh Z., Buyyounouski M., Wong H.P., Apte A.P., Price R.A., Hu J., **Pollack A.** Identification of a single nucleotide polymorphism related to late toxicity in a randomized Hypofractionation Trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 81:S156-S157, 2011.
  197. Patel V.N., Stoyanova R., Guruju R., Egleston B.L., **Pollack A.** Linked dual nomograms that consider radiation dose and length of androgen deprivation in the estimation of biochemical failure at five years. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 81:S385, 2011.
  198. Abramowitz M.C., Stoyanova R., Kava B., Soloway M., Manoharan M., Casillas J.,

- Pollack A.** Dynamic Contrast Enhanced MRI for the identification of prostate cancer in the prostate bed after radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 81:S410, 2011.
199. Tzou K.S., Buskirk S.J., Heckman M.G., Parker A.S., Patel V., Pelaez L., Hilton T.W., Peterson J.L., Vallow L.A., **Pollack A.** COX-2 expression does not predict biochemical failure in patients treated with salvage radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 81:S410-S411, 2011.
  200. Jean-Pierre P., Stoyanova R., Penedo F., Antoni M., Abramowitz M., Buyyounouski M., **Pollack A.** treatment-related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: A Phase III Hypofractionation Trial. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 81:S667, 2011.
  201. Stoyanova R., Garugu R., Bossart E., Wu X., **Pollack A.** A software platform for rapid translation of functional MRI findings to radiation treatment planning for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 81:S698-S699, 2011.
  202. Wu X., Gupta S., Umar S., Agarwal A.K., Portelance L., Stoyanova R., **Pollack A.**, Ahmed M.M. Space-time Fractionation (STF): A spacial concept whose time has come. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 81:S750, 2011.
  203. **Pollack A.**, Walker G., Stoyanova R., Khor L., Horwitz E., Buyyounouski M. Prospective Validation Of Diagnostic tumor Tissue Ki-67 As The Most Significant Predictor Of Outcome In Men Treated For Prostate Cancer On A Randomized Trial. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 84:S25-S26, 2012.
  204. Stoyanova R., Walker G., Sandler K., Khor L., Horwitz E., Buyyounouski M., **Pollack A.** Determinants of Prostate Biopsy Positivity 2 Years After Radiation Therapy for Men With Prostate Cancer Treated on a Randomized Trial. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) 84:S60, 2012.
  205. Abramowitz M.C., Bossart E., Freedman L., Ishkanian A., **Pollack A.** Noninvasive Real-Time Prostate Tracking Using a Transperineal ultrasound Approach: Phantom Studies and Initial Clinical Experience. Int. J. Radiat. Oncol. Biol. Phys. 84:S133, 2012.
  206. Huang KT, Walker R, Stoyanova R, Sandler K, Horwitz E, Buyyounouski MK, **Pollack A.** “Primary Prostate Radiation Therapy: Where Are We Failing?” Int. J. Radiat. Oncol. Biol. Phys. 84:S182, 2012.
  207. Ly B, Bossart E, **Pollack A.**, Amestoy W, Wright J. “Conventional Versus IMRT Planning for Palliation of Bone Metastases: A Dosimetric Comparison.” Int. J. Radiat. Oncol. Biol. Phys. 84:S632, 2012.
  208. Abramowitz MC Bossart E, Martin L, Brooks R, Lathulliere F, Laura F, Ishkanian A, **Pollack A.** “Noninvasive Real-Time Prostate Tracking Using a Transperineal Ultrasound: A Clinical Trial Comparison to RF Transponders with Visual Confirmation.” Int. J. Radiat. Oncol. Biol. Phys. 87:S682, 2013.
  209. Pardo DAD, Abramowitz M, Mahmoud O, Ishkanian A, Fernandez G, Shields J, Manoharan M, and **Pollack A.** “Neoadjuvant Radiation Therapy Improves Survival in Patients with T2b/T3 Invasive Bladder Cancer.” Int. J. Radiat. Oncol. Biol. Phys. 87:S399, 2013.
  210. Stoyanova R, Sandler K, **Pollack A.** Delineation and visualization of prostate cancer in multiparametric MRI. Pract Rad Oncol. 3 (2 Suppl 1): S30-S31, 2013.
  211. Abramowitz MC, Williams SG, Stephenson A, Kattan M, Pisansky TM, Klein EE, Anscher MS, Michalski J, Sandler HM, Forman JD, Zelefsky MJ, Kestin L, DeWeese TL, Liauw S, Valicenti RK, Kuban DA, **Pollack A.** Defining Long Term Failure Risk in Patients With an Undetectable PSA After Salvage Radiation. Int. J. Radiat. Oncol. Biol. Phys. 90:S131, 2014.

212. Brenneman R, Sullivan EJ, Berezhnoy A, Ishkanian F, Gilboa E, **Pollack A**, Ishkanian AS. 4-1BB Aptamer-Based Immunomodulation Enhances the Efficacy of Ionizing Radiation in a Preclinical Murine Tumor Model. Int. J. Radiat. Oncol. Biol. Phys. 90:S176, 2014.
213. Ly BH, William A, **Pollack A**, Bossart E, Wright J. Dose Escalation Using Conventional Versus IMRT Planning for Hypofractionated Radiation of Lumbosacral Metastases. Int. J. Radiat. Oncol. Biol. Phys. 90:S698, 2014.
214. Orman AG, Parra A, **Pollack A**, Stoyanova R, Abramowitz M. Automated Prostate Bed Lesion Detection: The Next Step in Salvage Radiation Therapy Dose Escalation. Int. J. Radiat. Oncol. Biol. Phys. 90:S461, 2014.
215. Orman AG, **Pollack A**, Stoyanova R, Wang K, Abramowitz M. A Phase 3 Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiation Therapy Postprostatectomy: The MAPS Trial, An Initial Dosimetric Assessment. Int. J. Radiat. Oncol. Biol. Phys. 90:S413, 2014.
216. Parra A, Orman A, Abramowitz M, **Pollack A**, Stoyanova R. Automatic Detection of the Foci of Residual or Recurrent Disease in the Prostate Bed After Prostatectomy Using Dynamic Contrast Enhanced-MRI. Int. J. Radiat. Oncol. Biol. Phys. 90:S821, 2014.
217. **Pollack A**, Abramowitz M, Bossart E, Reis I, Lynne C, Jorda M, Casillas V, Ishkanian A, Stoyanova R. Prostate Cancer Phase 1 Lattice Extreme Ablative Dose (LEAD) Trial: Feasibility and Acute Toxicity. Int. J. Radiat. Oncol. Biol. Phys. 90:S455, 2014.
218. Scott MT, Stoyanova R, Abramowitz MC, Casillas VJ, Islikanian A, Kwon D, Lynne C, **Pollack A**. MRI Ultrasound Fusion-Guided Biopsy of the Prostate: Results of Initial Experience in a Radiation Oncology Department. Int. J. Radiat. Oncol. Biol. Phys. 90:S207-S208, 2014.
219. Udayakumar T, Patel M, Betancourt D, Han T, Barber G, **Pollack A**. Radiation-Mediated Inhibition of IFN Signaling Sensitizes VSV Resistant Prostate Cancer Cells. Int. J. Radiat. Oncol. Biol. Phys. 90:S449, 2014.
220. Nelson AS, Piper J, Curry K, Swallen A, Padgett K, **Pollack A**, Stoyanova RS. Evaluation of An Atlas-Based Segmentation Method for Prostate and Peripheral Zone Regions On MRI. Med. Phys. 42:3606, 2015.
221. Padgett K, Pirozzi S, Nelson A, Stoyanova R, Piper J, Horvat M, Dogan N, **Pollack A**. Novel Validation Paradigm of MRI to CT Deformation of Prostate. Medical Physics. 42:3315-6, 2015
222. **Pollack A**, Erho N, Noronha R, Lam LLC, Buerki C, Abraham S, Klein EA, Karnes RJ, Den RB, Dicker A, Ishkanian A, Davicioni E, Feng FYC, Stoyanova R. A biomarker panel associated with distant metastasis in prostate cancer patients treated with radiotherapy as prognostic for DM in a large cohort of prostatectomy patients. J. Clin. Oncol. 33: S8, 2015.
223. Stoyanova R, **Pollack A**, Lynne C, Jorda M, Erho N, Lam LLC, Buerki C, Davicioni E, Ishkanian A. Using radiogenomics to characterize MRI-guided prostate cancer biopsy heterogeneity. Journal of Clinical Oncology. 33: S25, 2015.
224. Stoyanova R, Tachar M, Erho N, Lynne C, Abraham S, Patel M, Buerki C, Lam L, Jorda M, Kryvenko O, Ishkanian A, Abramowitz M, Davicioni E, **Pollack A**. Radiogenomics of MRI-Guided Prostate Cancer Biopsy Habitats. Med. Phys. 42:3605, 2015.
225. Studenski M, Stoyanova R, Abramowitz M, Dogan N, **Pollack A**. Heightened Apical Positivity of 2-Year Post-Radiotherapy Biopsies Is Not Related to Suboptimal Dosimetry. Med. Phys. 42:3437-8,2015.



1. **Pollack A**, Zagars GK, Sands ME. In response to editorial by Dr. M.V. Pilepich: Local treatment for prostate cancer - 90 years later. Int. J. Radiat. Oncol. Biol. Phys. 31:436, 1995.
2. Zagars GK, **Pollack A**, von Eschenbach AC, Ayala AG. In response to Drs. Hammond and Grignon: Gleason grade and other prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 31:435-6, 1995.
3. **Pollack A**, Zagars GK, Sands ME. In response to Drs. Wiegel and Bressel. Androgen-ablation for node-positive prostate cancer: The case for radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 32:896-7, 1995.
4. **Pollack A**, Zagars GK. Letter to the editor: Concerning prostate cancer cover story. TIME Magazine, p. 4, April 22, 1996.
5. **Pollack A**, Chaney A, Zagars GK. In response to Dr. Powell. Radiat. Oncol. Invest. 6:289-90, 1998.
6. **Pollack A**, Horwitz EM. Letter to the editor, RE: "Long-term urinary function after transperineal brachytherapy for patients with large prostate glands." Int. J. Radiat. Oncol. Biol. Phys. 53:512-3, 2002.
7. **Pollack A.**, Zagars GK, Antolak J, Kuban D, Rosen I. In response to Drs. Kagan and Schulz: Int. J. Radiat. Oncol. Biol. Phys. 55:1151-2, 2003.
8. **Pollack A**, Zagars GK, Antolak J, Kuban D, Rosen I. In response to Drs. Millar and Williams: Int. J. Radiat. Oncol. Biol. Phys. 55:1461-2, 2003.
9. **Pollack A.** In response to Drs. Lawrence and Crawford: Int. J. Radiat. Oncol. Biol. Phys. 57:1511, 2003.
10. Buyyounouski M, Hanlon AL, Uzzo RG, **Pollack A.** Letter to the editor, RE: "Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 Prostate Cancer: Results from the search database." J. Urol. 171:1246-7, 2004.
11. Horwitz EM, Feigenberg SJ, **Pollack A**, Hanks GE, Uzzo RG. Letter to the editor, RE: "6-month androgen suppression plus radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial." JAMA 292: 2084-5, 2004.
12. Buyyounouski M, Hanlon AL, Price RA, Horwitz EM, Feigenberg SJ, **Pollack A.** Letter to the editor RE: "Erectile dysfunction and radiation dose to penile base structures: a lack of correlation." Int. J. Radiat. Oncol. Biol. Phys. 60:1664-5, 2004.
13. **Pollack A**, Eade TM, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE. Response to letters to the editor RE: "What external beam radiation dose is high enough for prostate cancer?" Int. J. Radiat. Oncol. Biol. Phys. 68: 682-9, 2007.
14. **Pollack A**, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, Stoyanova R, Movsas B, Greenberg RE, Uzzo RG, Ma C, Buyyounouski MK. Response to letters to the editor RE: Reply to M Brenner, et al and I Vogelius, et al; J Clin Oncol. 32: 1853-4, 2014

**19. Other works accepted for publication:** None

## **V. PROFESSIONAL**

### **20. Funded Research Performed (includes grants received in the last six years):**

#### **Grant and Contract Support Active:**

Role: Principal Investigator 2014-2019  
Source: NIH-NCI (R01CA189295)  
Title: MRI Imaging and Genetic Signatures to Manage Prostate Cancer Overdiagnosis  
Amount: \$3,017,627 (Total Cost)

Role: Co-Principal Investigator (PI: Gillies) 2014-2018  
Source: NIH-NCI (R01CA190105)  
Title: (PQC4) Habitats in Prostate Cancer  
Amount: \$2,773,731 (Total Cost)

Role: Principal Investigator 2014-2015  
Source: SCCC Clinical Trials Acceleration Grant  
Title: A Phase II Randomized Trial of MRI-Guided Prostate Boosts via Initial Lattice Stereotactic vs. Daily Moderately Hypofractionated Radiotherapy – The Miami BLaStM Trial  
Amount: \$100,000 (Total Cost)

#### **Grant and Contract Support Completed Since 2009:**

Role: Principal Investigator 2010-2014  
Source: NIH-NCI (5R21CA153826)  
Title: MRI-Guided Radiotherapy and Biomarkers for Prostate Cancer  
Amount: \$408,775 (Total Cost)

Role: Principal Investigator 2010-2013  
Source: Bankhead Coley Cancer Research Program – Team Science Project 10BT03  
Title: Biomarkers for Men Treated Primarily with Radiotherapy  
Amount: \$1,200,000 (Total Cost)

Role: Principal Investigator 2009-2013  
Source: NIH-NCI (5-R21-CA-133632-03)  
Title: Biomarker Models for Prostate Cancer Outcome After Radiotherapy  
Amount: \$268,083 (Total Cost)

Role: Principal Investigator 2009-2013  
Source: M0902125 (Pollack)  
Title: American College of Radiology/Radiation Therapy Oncology Group (5-U10-CA-021661-38)  
Amount: \$ 216,410 (Total Cost)

Role: Principal Investigator 2010-2012  
Source: Bankhead-Coley Cancer Research Program (09BW11)  
Title: Genomic and Dosimetric Determinants of Radiotherapy Outcome in Prostate Cancer

Amount: \$819,593 (Total Cost)

Role: Principal Investigator 2010-2012  
Source: Bankhead-Coley Cancer Research Program (09BW10)  
Title: Prostate Cancer Imaging and Gene Therapy Delivery Using a Nanosphere Vector  
Amount: \$708,260 (Total Cost)

Role: Principal Investigator 2009-2011  
Source: SCCC - 304875  
Title: Genetic and Dosimetric Determinants of Toxicity in Men Treated with Radiotherapy for Prostate Cancer  
Amount: \$60,000 (Total Cost)

Role: Co-investigator 2008-2011  
Source: DOD Idea Development Award PC073127 (PI: L. Chen)  
Title: “MR-Guided, Pulsed, High-Intensity, Focused Ultrasound and Radiotherapy for Prostate Cancer Treatment”  
Amount: \$375,000 (Direct cost)

Role: Principal Investigator 2003-2009  
Source: NIH: R01 CA101984-01  
Title: “Radiation, Hormones & Antisense Prostate Cancer Therapy”  
Amount: \$2,450,605 (Direct Cost)

Role: Principal Investigator 2006-2009  
Source: Pennsylvania Commonwealth Universal Research Enhancement  
Title: Biomarkers for Prostate Cancer Treatment with Radiation and Hormone Therapy  
Amount: \$260,412 (Total cost)

Role: Co-Investigator 2005-2009  
Source: NIH: 1R01CA108890-01A1 (PI: V. Kolenko)  
Title: Role of Zinc in Prostate Carcinogenesis  
Amount: \$1,201,740

**Grant Study Sections/External Advisor Meetings (since 2005):**

Ad-hoc participant NIH Radiation Therapeutics and Biology Study Section, Ventura, CA, January 2005.

Ad-hoc participant NIH Radiation Therapeutics and Biology Study Section, Bethesda, MD, June 2005.

Ad-hoc participant NIH Radiation Therapeutics and Biology Study Section, Bethesda, MD, October 2005.

Ad-hoc participant NIH Radiation Therapeutics and Biology Study Section, Washington, DC, January 2007.

Ad-hoc participant NIH Radiation Therapeutics and Biology Study Section, Bethesda, MD, October 2007.

Member, Prostate SPORE External Advisory Committee, Mayo Clinic, Rochester, MN, March 2008 – Present.

Ad-hoc participant Scientific Review Group, Clinical and Translational Imaging Applications, June 2012.

Ad hoc participant NIH Special Emphasis Panel Review, Academic-Industrial Partnerships for

Translation of in vivo Imaging Systems for Cancer Investigations, June 2013.  
 Ad-hoc participant in Special Emphasis Panel: ZRG1 SBIB-Z (83) Biomedical Imaging and Engineering Area Review, June, 2014  
 Ad-hoc participant in NIH special emphasis panel: ZRG1 SBIB-Z (58) "Image-Guided Drug Delivery in Cancer", March, 2015

**21. Editorial responsibilities [with inclusive dates]:**

Ad Hoc reviewer for several journals  
 Editorial Board: Int. J. Radiat. Oncol. Biol. Phys. 1998-2011  
 Guest Co-editor: Special Section of the Int. J. Radiat. Oncol. Biol. Phys. 2000  
 (vol 48, pp 427, 2000), 2<sup>nd</sup> Annual S. Takahashi Memorial 3DCRT  
 Conference, Nagoya, Japan.  
 Guest Co-editor: Special Section of the Int. J. Radiat. Oncol. Biol. Phys. 2003  
 (vol 56, pp 82, 2003), 3<sup>rd</sup> Annual S. Takahashi Memorial 3DCRT  
 Conference, Nagoya, Japan.  
 Section Editor, Radiation Oncology, Cancer 2005-2011  
 Editorial Board: J. Clin. Oncol. 2008-2013

**22. Professional and Honorary Organizations:**

American Association for Cancer Research  
 American College of Radiology  
 Florida Radiological Society  
 American Society of Clinical Oncology  
 American Society of Therapeutic Radiology and Oncology  
 Member, Education Committee  
 Gilbert H. Fletcher Society  
 Radiological Society of North America  
 Society of Chairman of Academic Radiation Oncology Programs  
 American Radium Society, Treasurer, 2008-2010  
 American Radium Society, President Elect, 2010-2011  
 American Radium Society, President, 2011-2012  
 American Radium Society, Past President, 2012-2013

**23. Honors and Awards**

University of Miami School of Medicine 1976-1979  
 Surgical Scholarship Fund Fellowship  
 Department of Surgery  
 Miami, FL  
 The Thomas Brown McClelland Trust Scholarship 1987  
 Rotary Club of Miami, Miami, FL  
 Radiological Society of North America Fellowship 1991-1992  
 Am. Soc. for Therapeutic Radiology and Oncology Fellowship 1991-1992  
 Support for project "Solid tumor repopulation kinetics after  
 x-irradiation using antibodies to bromodeoxyuridine  
 and iododeoxyuridine"  
 American Cancer Society Career Development Award 1993-1996

"Cell Kinetic Analysis of Human Solid Tumors after Labeling with Two Thymidine Analogues"

Clinical Researcher of the Year  
University of Miami Miller School of Medicine  
Outstanding Faculty Awards

2015

**24. Post-Doctoral Fellowships:**

None

**25. Other Professional Activities (e.g. papers presented; performances; conference proceedings; seminar or conference panel member; catalogue work; etc):**

**Organizational Committees/Meeting Session Moderation (Since 2005):**

NCCN Bladder Cancer Guidelines Panel, Chicago, IL, 2000 – 2008.

Invited participant of the Select Grant Steering Committee, representing the RTOG, Seattle, WA, April 2000.

Section Leader or co-leader, RTOG, GU Translational Research Program, 1998-Present.

Member, RTOG GU Strategy Committee, 1998-Present.

NCCN Prostate Cancer Early Detection Guidelines Panel, 2001–2007.

NCCN Prostate Cancer Guidelines Panel, 2001 – 2007.

Panelist, "Dose Escalation for Prostate Cancer: Three Different Methods," 43<sup>rd</sup> Annual Meeting of the American Association for Therapeutic Radiology and Oncology, San Francisco, CA, November 2001.

Moderator for the Genitourinary Scientific Session during the 43<sup>rd</sup> Annual Meeting of the American Association for Therapeutic Radiology and Oncology, San Francisco, CA, November 2001.

Panelist "Update: Bladder Cancer Guidelines" at the NCCN 7<sup>th</sup> Annual Conference: Practice Guidelines and Outcomes Data in Oncology, Hollywood, FL, March 2002.

American Board of Radiology Examiner – radiation oncology oral examinations, 2001-Present

Participant, ATC Optimization Collaborative Working Group, Rockville, MD, February 2003.

Participant, PCABC Prostate Committee, initial teleconference, February 2003.

Genitourinary abstract reviewer for ASTRO, 2003.

Moderator Genitourinary Scientific Session during the 45<sup>th</sup> Annual Meeting of the American Association for Therapeutic Radiology and Oncology, Salt Lake City, UT October 2003.

Member, IUCC GU Committee, 2004-Present.

Moderator – Scientific Session: External Beam Outcome for ASTRO, Atlanta, GA, 2004.

Panelist – Genitourinary Panel during the 87<sup>th</sup> Annual Meeting of the American Radium Society, Barcelona, Spain, May 2005.

Member, ARS Scientific Program Committee, 2005-2007.

Co-Chair, RTOG Symposium "Bioinformatics and CaBIG" 2006.

Chair and participant: "Hypofractionation 2006, A Short Cut to the Future," Philadelphia, PA, November 2006.

Moderator Genitourinary Scientific Session during the 88<sup>th</sup> Annual Meeting of the American Radium Society, Maui, HI, May 2006.

Member, GU Section Item Rating committee for written exams, 2006.

American Board of Radiology – Head of GU section for oral exam, 2006-2011.

Member Task Force on Oncologic Imaging and Therapies, Radiological Society of North America, 2006.

Member, AJCC GU Committee, 2006-2012.

Chair, Scientific Program Committee, American Radium Society meeting for May 2008.  
 Member, Executive Committee, American Radium Society, 2007-Present.  
 Chair, organizing committee and participant: "Hypofractionation 2011" Miami, FL, October, 2011.  
 Moderator – Scientific Session: SS Q.GU II – Prostate Cancer: Prognostic Factors, ASTRO, Boston, MA, 2012.  
 Moderator – Imaging Scientific Session during the 95<sup>th</sup> Annual Meeting of the American Radium Society, Scottsdale, AZ, April 2013.  
 Genitourinary abstract reviewer for ASTRO, 2013  
 Genitourinary abstract reviewer for ASTRO 2014  
 Genitourinary abstract reviewer for ASTRO 2015  
 Discussant of abstracts in ASTRO session QQ, Biomarkers, San Antonio, TX, October, 2015  
 Discussant – ASTRO Plenary Session Abstract, San Antonio, Tx, October, 2015

**Consultant/Advisory Boards:**

Coulter Electronics Hialeah, FL	Consultant, E.A.S.Y. Computer System Software Development, P.I.: B. Bagwell	1983-1985
Univ. of Miami Sch. of Medicine Dept. of Microbiol. & Immunol. Miami, FL	Consultant, NIH Grant "Halopyrimidine tumor radiosensitization: new strategies." P.I: S. Greer	1984-1985
Calypso Medical Systems Boston, MA	Consultant	2003-2006
Hayword Medical Comm. New Market, U.K.	Consultant Plenaxis	2008
GE Healthcare Milwaukee, WI	Consultant Radiation Oncology Usability Study	2013
City of Hope Comprehensive Cancer Center Duarte, CA	External Advisory Board	2/2014 - Present
Liquidnet, Inc. New York, NY	Consultant	6/2014
Medivation Services, Inc. San Francisco, CA	Consultant	9/2014

**VI. TEACHING**

- 26. Teaching Awards Received:** None
- 27. Teaching Specialization (courses taught, new courses developed, innovative or**



14. **Pollack A.** "Patients with locally-advanced non-metastatic prostate cancer should receive total androgen ablation: The Con View." Lecture at Southern Association for Oncology 9th Annual Meeting - Controversies in Oncology - Williamsburg, VA, August 1996.
15. **Pollack A.** "The role of androgen ablation in the treatment of prostate cancer with radiotherapy." Texas Radiological Society Meeting, Houston, TX, September 1996.
16. **Pollack A.** "New advances in Radiation Oncology." Lecture at 5th Annual Fall Conference - Current Trends in Prostate & Testicular Cancer - Klabzuba Cancer Center, Harris Methodist Fort Worth Education Center, Fort Worth, TX, October 1996.
17. **Pollack A.** "Current Status of Androgen Ablation Plus External Beam Radiotherapy for Regionally Localized Prostate Cancer." Providence Memorial Hospital - 14th Annual Western Regional Oncology Conference, El Paso, TX, January 1997.
18. **Pollack A.** "Radiotherapeutic Management of Soft Tissue Sarcomas." American Society for Therapeutic Radiology and Oncology (ASTRO) Refresher Course, Dallas, TX, March 1997.
19. **Pollack A.** "External beam radiotherapy for prostate cancer - How does it stack up?" Texas Radiological Society Meeting, El Paso, TX, April 1997.
20. **Pollack A.** "Radiotherapy for prostate cancer in the 1990's." Texas Society of Radiologic Technologists Annual Meeting, Houston, TX, April 1997.
21. **Pollack A.** "Androgen ablation in the management of regionally localized prostate cancer." Current Management of Cancer, Spohn Health System's Fifth Annual Oncology Conference, Corpus Christi, TX, April 1997.
22. **Pollack A.** "Prostate cancer treated with external beam radiotherapy: Pretreatment prognostic factors." Advantage Healthcare Inc., First Sonoma Conference on Prostate Cancer, Sonoma, CA, June 1997.
23. **Pollack A.** "External beam radiotherapy for prostate cancer: How does it stack up?" Keynote address at genitourinary radiation oncology session, Annual Meeting of the Radiological Society of North America, Chicago, IL, November 1997.
24. **Pollack A.** "Management of regionally localized high risk prostate cancer." Radiological Society of North America National Meeting Refresher Course, Chicago, IL, November 30-December 1997.
25. **Pollack A.** "The prospects for bladder preservation: For whom and how?" The Sixth Annual Genitourinary Oncology Conference on Clinical Advances in the Treatment of Genitourinary Tumors, Houston, TX, February 1998.
26. **Pollack A.** "Optimal integration in the management of unfavorable prostate cancer." The Sixth Annual Genitourinary Oncology Conference on Clinical Advances in the Treatment of Genitourinary Tumors, Houston, TX, February 1998.
27. **Pollack A.** "Androgen ablation plus radiation for prostate cancer: A decline or delay in failure?" The 23<sup>rd</sup> Annual Meeting of the Gilbert H. Fletcher Society, Houston, TX, April 1998.
28. **Pollack A.** "PSA nadirs after EBRT." American Brachytherapy Society, Albuquerque, NM, May -June 1998.
29. **Pollack A.** "Issues in the management of locally advanced prostate cancer." Panel Session, American Society for Therapeutic Radiology and Oncology, Phoenix, AZ, October 1998.
30. **Pollack A.** "Radiotherapy for prostate cancer." MD Anderson Outreach Speakers Bureau-Prostate Cancer, McAllen, TX, November 1998.
31. **Pollack A.** "Radiation therapy for high-risk prostate cancer." 1998 Radiological Society of North America Refresher Course, Chicago, IL, November -December 1998.
32. **Pollack A.** "The role of androgen ablation plus radiation in the treatment of prostate cancer." Kyoto University Hospital, Kyoto, Japan, December 1998.



33. **Pollack A.** “Dose-escalation in the treatment of prostate cancer using 3-dimensional conformal radiotherapy.” 2<sup>nd</sup> S. Takahashi Memorial International Conference on 3-Dimensional Conformal Radiotherapy, Nagoya, Japan, December 1998.
34. **Pollack A.** “Treatment of high risk prostate cancer with androgen ablation and radiotherapy.” Lecture sponsored by TAP Pharmaceutical, U. T. M.D. Anderson Medical Oncologists and Fellows, Churoscos Restaurant, Houston, TX, February 1999.
35. **Pollack A.** “External beam irradiation and hormonal therapy for prostate cancer.” New Advances in Brachytherapy & Prostate Cancer Management,” Scottsdale, AZ, February 1999.
36. **Pollack A.** “Androgen ablation and external beam radiotherapy for regionally localized high risk prostate cancer.” Spohn Health Systems, Corpus Christi, TX, March 1999.
37. **Pollack A.** “An update of the role of radiation therapy in the management of bladder cancer.” Radiation Oncology Grand Rounds, Mount Sinai Medical Center, Department of Radiation Oncology, New York, NY, March 1999.
38. **Pollack A.** “Treatment planning techniques and considerations using conformal radiotherapy in the treatment of localized prostate cancer” and “Evidence for a dose-response in prostate cancer using external beam radiotherapy.” Texas Radiological Society Annual Meeting, Dallas, TX, April 1999.
39. **Pollack A.** “Conformal radiotherapy for prostate cancer: The MD Anderson Experience.” International Symposium on 3D Conformal Radiation Therapy and Intensity Modulated Radiation Therapy in the New Millennium, Houston, TX, April -1999.
40. **Pollack A.** “Radiotherapy for prostate cancer,” in refresher course entitled “Management of advanced carcinoma of the prostate.” American Urological Association Annual Meeting, Dallas, TX, May 1999.
41. **Pollack A.** A series of 14 lectures on prostate, bladder, and testis cancer, Sydney, Melbourne, Perth, Brisbane, Adelaide and Newcastle, Australia, May 1999.
42. **Pollack A.** “Management of regionally localized high risk prostate cancer with androgen ablation and radiotherapy.” Lecture sponsored by TAP Pharmaceuticals, UTMD Anderson Cancer Center Medical Oncologists and Fellows, Houston, TX, July 1999.
43. **Pollack A.** “Man-to-Man Prostate Support Group.” Northeast Regional Cancer Center, Humble, TX, September 1999.
44. **Pollack A.** “Radiotherapy versus surgery for prostate cancer.” Genesys Hurley Cancer Institute, Flint, MI, September 1999.
45. **Pollack A.** “Prostate cancer: The Y2K dilemma.” North Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Dartmouth, NH, October 1999.
46. **Pollack A.** “Conformal radiotherapy for prostate cancer.” MD Anderson Associate’s Conference, UTMD Anderson Cancer Center in Houston, TX, October 1999.
47. **Pollack A.** 1) “Treatment of early prostate cancer: External beam versus implant versus surgery” and 2) “High risk prostate cancer: The role of androgen ablation and radiation.” Julie & Ben Rogers Cancer Institute, Beaumont, TX, October 1999.
48. **Pollack A.** “Treatment of prostate cancer with radiotherapy: New directions.” St. Joseph Medical Center, Tulsa, OK, November 1999.
49. **Pollack A.** “Radiotherapy for prostate cancer: Pushing the envelope beyond the conventional treatment.” Institutional Grand Rounds, UTMD Anderson Cancer Center, Houston, TX, November 1999.
50. **Pollack A.** “Management of regionally localized, high-risk prostate cancer.” Refresher Course - RSNA, Chicago, IL, November 1999.
51. **Pollack A.** “Management of primary prostate cancer from the perspective of radiation oncologist.” UTMD Anderson Cancer Center, Medical Grand Rounds Seminar, Houston, TX, December 1999.

52. **Pollack A.** “Radiotherapy for prostate cancer: Pushing the envelope.” University of Utah Health Sciences, Salt Lake City, UT, December 1999.
53. **Pollack A.** “Dose-escalation with 3-D conformal radiation for prostate cancer.” Moderator for panel: Controversies in prostate cancer. UTMD Anderson RadOnc2000, Houston, TX, February 2000.
54. **Pollack A.** “Dose escalation: Optimizing patient and dose selection.” Prostate Cancer in the New Millennium, Scottsdale, AZ, March 2000.
55. **Pollack A.** “Current status of XRT.” UTMD Anderson Cancer Center, Genitourinary Medical Oncology Conference, Houston, Texas, March 2000.
56. **Pollack A.** “Prostate cancer: balancing radiation dose and androgen ablation.” Fox Chase Cancer Center, Philadelphia, PA, April 2000.
57. **Pollack A.** “External beam radiation therapy conventional versus 3D conformal treatment.” UTMD Anderson Cancer Center, Clinical Innovations in the Diagnosis and Treatment of Localized Prostate Cancer Conference, Houston, TX, April 2000.
58. **Pollack A.** “Neoadjuvant hormonal therapy: A synergistic effect with radiotherapy.” UTMD Anderson Cancer Center, Clinical Innovations in the Diagnosis and Treatment of Localized Prostate Cancer Conference, Houston, TX, April 2000.
59. **Pollack A.** “Management and treatment of advanced carcinoma of the prostate.” 2000 AUA Meeting, Atlanta, GA, April 2000.
60. **Pollack A.** “Prostate cancer radiosensitization from androgen ablation.” Mechanisms of Cell Death and Disease: Advances in Therapeutic Intervention Conference, Dublin, Ireland, May 2000.
61. **Pollack A.** “Does XRT add anything to androgen ablation?” Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, May 2000.
62. **Pollack A.** “Acute and late treatment toxicity: Perspectives on a randomized trial.” Fifth International Symposium on 3D Conformal Radiation Therapy and Brachytherapy, Memorial Sloan-Kettering Cancer Center, New York, NY, June 2000.
63. **Pollack A.** “Management of regionally localized, high risk prostate cancer.” Kaiser Permanente Hematology Oncology Symposium, Bellflower, CA, June 2000.
64. **Pollack A.** “Conformal radiotherapy for prostate cancer-The MD Anderson Experience.” ASTRO Workshop Clinical Implementation of 3-D Conformal Radiation Therapy for Prostate Cancer, Chicago, IL, June 2000.
65. **Pollack A.** “Clinical issues on implementing IMRT MD perspective.” IMRT Seminar, Sponsored by Varian Pharmaceuticals, Cincinnati, OH, October 2000.
66. **Pollack A.** “Radiotherapy for intermediate-to-high risk prostate cancer: Converging on success.” Detroit, MI, October 2000.
67. **Pollack A.** “The road to IMRT for prostate cancer.” MD Anderson Cancer Center at Orlando, Orlando, FL, October 2000.
68. **Gius D, Pollack A.** “Novel biologic therapies combined with radiation – with an emphasis on gene therapy and anti-angiogenesis.” Refresher course at ASTRO annual meeting, Boston, MA, October 2000.
69. **Pollack A.** “Conformal radiotherapy: Comparisons between conventional radiotherapy and conformal radiotherapy.” Controversies In Prostate Cancer Radiotherapy, Vancouver, BC, November 2000.
70. **Pollack A.** “Androgen ablation plus radiation: Biology of interaction.” Controversies In Prostate Cancer Radiotherapy, Vancouver, BC, Canada, November 2000.
71. **Pollack A.** “Management of regionally localized, high risk prostate cancer.” Refresher course at RSNA 2000 Annual Meeting, Chicago, IL, November 2000.

72. **Pollack A.** “Androgen ablation in high risk prostate cancer: Clinical data and review.” 53<sup>rd</sup> Annual Midwinter Radiation Oncology Conference, LARS/SCROS, Beverly Hills, CA, January 2001.
73. **Pollack A.** “New approaches to the patient with localized prostate cancer: The role of radiation therapy.” Scripps Cancer Center Clinical Hematology and Oncology 2001 Conference, La Jolla, CA, February 2001.
74. **Pollack A.** 1) “Treatment for low risk patients: Why I prefer external beam irradiation” 2) “EBRT + hormones” 3) “Radiation dose and external beam irradiation” 4) “What should PSA be after treatment with external beam?” and “EBRT for rising PSA following radical prostatectomy.” Diversified Conference Management, Inc. (DCMI) 6<sup>th</sup> Annual Scottsdale Prostate Cancer Symposium, Scottsdale, AZ, February 2001.
75. **Pollack A.** “Bladder cancer.” ASTRO Spring Refresher Course, Chicago, IL, March 2001.
76. **Pollack A.** “Clinical issues implementing IMRT.” Sponsored by Varian Medical Systems, Seattle IMRT Seminar, Seattle, WA, March 2001.
77. **Pollack A.** “Prostate IMRT experience at MD Anderson.” 3D Radiation Therapy Conference 2001, Williamsburg, VA, June 2001.
78. **Pollack A.** “Radiation dose response and the role of IMRT.” Fox Chase Network Physician Education Symposium and Scientific Meeting, Fox Chase Cancer Center, Philadelphia, PA, September 2001.
79. **Pollack A.** 1) “Androgen ablation plus radiation for high risk regionally localized prostate cancer,” and 2) “Prostate cancer radiation dose response.” University of Pennsylvania Medical Center, Philadelphia, PA, September 2001.
80. **Pollack A., et al.** “Impact of ADT on survival in men treated with radiation.” Second International Conference on Newer Approaches to Androgen Deprivation Therapy in Prostate Cancer, Cambridge, MA, November 2001.
81. **Gius D, Pollack A.** “Novel combinations of biologic and radiation therapy-Emphasizing gene and anti-angiogenic therapeutic strategies” Refresher course - ASTRO Annual Meeting, San Francisco, CA, November 2001.
82. **Pollack A.** “Treatment of high risk patients with EBRT plus androgen ablation,” and “The role of brachytherapy in the management of localized prostate cancer.” Multidisciplinary GU Oncology, Cleveland, OH, November 2001.
83. **Pollack A.** “Radiation dose response and the role of IMRT in the treatment of prostate cancer.” Fox Chase Cancer Center, Philadelphia, PA, December 2001.
84. **Pollack A.** 1) “Technical considerations for IMRT implementation for prostate cancer,” and 2) “The impact of 3D-CRT/IMRT on prostate cancer control and morbidity.” 3<sup>rd</sup> International Workshop on 3D Conformal Radiotherapy, Nagoya, Japan, December 2001.
85. **Pollack A.** 1) “Dose escalation using EBRT for prostate cancer” and 2) “IMRT Technique and the need for prostate localization during radiotherapy for prostate cancer.” ASTRO 3D CRT/IMRT Practicum, St. Petersburg, FL, February 2002.
86. **Pollack A.** “Role of combined modality therapy in the treatment of prostate cancer.” Princess Margaret Hospital, Dept. of Radiation Oncology, Toronto, Canada. February 2002.
87. **Pollack A.** “Management strategies for intermediate risk prostate cancer.” Uro-oncology Meeting, Toronto, Canada, February 2002.
88. **Pollack A.** 1) “IMRT technique and the need for prostate localization during radiotherapy for prostate cancer” and 2) “Dose escalation using EBRT for prostate cancer” 7<sup>th</sup> Annual Scottsdale Prostate Cancer Symposium, Scottsdale, AZ, February 2002.
89. **Pollack, A.** “Radiation dose escalation reduces distant metastasis and increases survival for men with prostate cancer.” American Radium Society 84<sup>th</sup> Annual Meeting, Las Croabas, Puerto Rico, April 2002.

90. **Pollack A.** “External radiotherapy of prostate cancer: Hormo-radiation or high dose conformation? ICRO/ORGO 7, Salzburg, Austria, May 2002.
91. **Pollack A.** “Which radiation method is best for prostate cancer?” Society of Urologic Oncology Meeting, Orlando, FL, May 2002.
92. **Pollack A.** “Prostate cancer dose response to conformal radiotherapy” American Urologic Association Annual Meeting, Orlando, FL, May 2002.
93. **Pollack A.** “BAT – Clinical Experience.” Nomos - BAT Users Meeting, Dallas, TX, August 2002.
94. **Pollack A.** “Management of local-regional high risk prostate cancer with external beam radiotherapy and androgen ablation.” Aultman Cancer Center 2<sup>nd</sup> Annual Cancer Conference, Canton, OH, September 2002.
95. **Pollack A.** “FCCC prostate IMRT experience.” Monmouth Medical Center 3<sup>rd</sup> Annual Community Cancer Center IMRT Symposium. Long Branch, NJ, September 2002.
96. **Pollack A.** “Prostate cancer treatment: Radiation.” 2002 Cancer Symposium on Controversies in Cancer Care, MBNA Bowman Conf Center, Newark, DE, October 2002.
97. **Pollack A.** “IMRT for Prostate Cancer.” 21<sup>st</sup> Century Oncology Physicians’ Retreat, Bonita Springs, FL, October 2002.
98. **Pollack A.** “New directions in the management of cancer with external beam radiotherapy.” Keynote Address at the Second Annual US Cyberknife/First Worldwide Cyberknife Users’ Meeting, Napa, CA, November 2002.
99. **Pollack A.** 1) “External beam radiotherapy – Is more better?” 2) “Combining radiation and hormones: How can we do it?” 3) “Surgery vs. radiotherapy – The debate continues.” New Perspectives on Prostate Cancer, Ninth Cancer Symposium, Washington Adventist Hospital, Greenbelt, MD, November 2002.
100. **Pollack A.** “New techniques in radiation oncology.” Grand Opening of the Booker Radiation Oncology Center, Riverview Medical Center, Red Bank, NJ, January 2003.
101. **Pollack A.** “How to determine and delineate target volumes III (prostate).” Target Delineation Symposium for IMRT/3D CRT Treatment Planning, Houston, TX, January 2003.
102. **Pollack A.** “GU-TRP results and strategy.” RTOG Semi-Annual Meeting, Houston, TX, January 2003.
103. **Pollack A.** “Radiation therapy for clinically-localized prostate cancer.” Multidisciplinary Advances in the Treatment of Prostate Cancer, University of North Carolina at Chapel Hill, Chapel Hill, NC, February 2003.
104. **Pollack A.** “IMRT in prostate cancer.” ASTRO Practicum – Implementing IMRT in Clinical Practice, San Diego, CA, February 2003.
105. **Pollack A.** “Dose escalation as a rationale for developing an IMRT program for prostate cancer.” University of VA, Charlottesville, VA, March 2003.
106. **Pollack A.** “Therapeutic options for radiation therapy in prostate cancer.” Current Approaches in Cancer Therapy. Williamsburg, VA, March 2003.
107. **Pollack A.** 1) “Modulation of prostate cancer cell death in response to androgen deprivation and radiation by MDM2” 2) “Androgen deprivation plus radiotherapy for prostate cancer. Is it as effective as it appears?” 3) “Prostate cancer radiotherapy dose response: A rationale for IMRT.” ICRT 2003, Lugano, Switzerland, March 2003.
108. **Pollack A.** “Androgen deprivation plus radiotherapy for prostate cancer.” 11<sup>th</sup> Annual Radiation Workshop, Round Top, TX, March 2003.
109. **Pollack A.** “Androgen deprivation and radiation for high risk prostate cancer patients.” AstraZeneca: Radiation Oncology Residents’ Educational Dinner Program, Philadelphia, PA, April 2003.

110. **Pollack A.** “IMRT for prostate cancer.” 7<sup>th</sup> International Symposium on 3DCRT and IMRT, San Francisco, CA, April 2003.
111. **Pollack A.** “IMRT for prostate cancer: Do we have a leg to stand on?” FCCC Radiation Oncology Conference for Nurses, Therapists, and Dosimetrists, Philadelphia, PA, May 2003.
112. **Pollack A.** “Prostate cancer radiotherapy dose response: A rationale for IMRT.” Visiting Professor, Baylor College of Medicine, Houston, TX, May 2003.
113. **Pollack A.** “Androgen deprivation plus radiation for prostate cancer.” Baylor College of Medicine, Houston, TX, May 2003.
114. **Pollack A.** 1) “New techniques of radiotherapy for malignant tumors” 2) “Radiotherapy of early stage prostate cancer” 3) “Prostate cancer: Advantages of conformal and IMRT techniques.” Co-Chair: Conference, American Russian Cancer Alliance, Moscow, Russia, June 2003.
115. **Pollack A.** “IMRT for prostate cancer.” American Association of Physicists in Medicine Summer School Colorado Springs, CO, June 2003.
116. **Pollack A.** 1) “Androgen deprivation plus radiotherapy for prostate cancer” 2) “Therapeutic options for prostate cancer” 3) “Prostate cancer 3DCRT vs. IMRT: How do I treat?” and 4) “Innovations in radiation oncology.” Sirio Libanes Hospital, Sao Paulo, Brazil, July 2003.
117. **Pollack A.** “Androgen deprivation plus radiotherapy for clinically localized high risk prostate cancer.” St. Barnabas Hospital, Livingston, NJ, September 2003.
118. **Pollack A.** “Radiotherapy for prostate cancer: past, present and future.” City of Hope, Duarte, CA, September 2003.
119. **Pollack A.** “What’s All the Buzz...Intensity Modulated Radiation Therapy (IMRT).” Eighth Annual Prostate Cancer Conference, Bala Cynwyd, PA, September 2003.
120. **Pollack A.** “IMRT for Prostate Cancer: Image Guided Hypofractionation.” 3<sup>rd</sup> Japan-US Treatment Symposium, Kyoto, Japan, October 2003.
121. **Pollack A.** “Intensity modulated radiation therapy for prostate cancer.” Grandview Hospital, Sellersville, PA, October 2003.
122. **Pollack A.** 1) “XRT for high risk disease” 2) “Management of primary treatment failure.” San Diego Radiological Society – Advanced Prostate Cancer Symposium. San Diego, CA, November 2003.
123. **Pollack A.** “Balancing dose response and complication risk: A rationale for IMRT for prostate cancer.” 4<sup>th</sup> Annual Community Cancer Center IMRP Symposium, Monmouth Medical, Eatontown, NJ, November 2003.
124. **Pollack A.** Poster presentation, “Antisense Bcl-2 (Genasense<sup>TM</sup>) sensitizes prostate cancer cells to radiation.” AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, November 2003.
125. **Pollack A.** “Ki67 Staining is a strong predictor of patient outcome for prostate cancer patients treated with androgen deprivation plus radiotherapy: An analysis of RTOG 92-02.” RTOG Semi-Annual Meeting, Publications Scientific Session, New Orleans, LA, January 2004.
126. **Pollack A.** “IMRT for prostate cancer.” ASTRO Practicum – Implementing IMRT in Clinical Practice, San Diego, CA, February 2004.
127. **Pollack A.** “Radiosensitization using antisense strategies.” Varian Research Partners Symposium, Lake Mary, FL, January 2004.
128. **Pollack A.** “Dose escalation for prostate cancer: Should we, for whom, and how much?” American Radium Society Meeting 2004, Napa Valley, CA, May 2004

129. **Pollack A.** “Radiotherapy for prostate cancer.” In refresher course entitled “Treatment of organ confined, locally advanced and metastatic prostate cancer.” American Urological Association, Annual Meeting, San Francisco, CA, May 2004
130. **Pollack A.** “Treatment of intermediate and high risk localized prostate cancer.” Fox Chase Cancer Center sponsored CME course on Prostate Cancer 2004: Challenges in Treatment. Philadelphia, PA, May 2004
131. **Pollack A.** “Prostate cancer markers of outcome after radiation therapy.” RTOG Semi-Annual Meeting, Washington, DC, June 2004
132. **Pollack A.** “GU lecture.” Integrating Novel Agents with Radiotherapy in the Treatment of Solid Tumors Conference. Lake Tahoe, NV, July 2004.
133. **Pollack A.** “IMRT optimization and operations research.” AAPM 46<sup>th</sup> Annual Meeting, Pittsburgh, PA, July 2004.
134. **Pollack A.** “Dose escalation for prostate cancer and the roles of lymph node treatment and androgen deprivation.” AstraZeneca Urology Program, DVA NJ Healthcare System, East Orange, NJ, August 2004.
135. **Pollack A.** “Prostate cancer treated with radiotherapy.” Papageorgiou General Hospital, Thessaloniki, Greece, September 2004.
136. **Pollack A.** Panel: “Prostate hypofractionation – progress or peril?” ASTRO Annual Meeting, Atlanta, GA, October 2004.
137. **Pollack A.** “Therapeutic options for prostate cancer.” 2004 VICCAN Fall Scientific Meeting, Stone Mountain, GA, October 2004.
138. **Pollack A.** “Adaptive radiotherapy.” Siemens Executive Exchange, Cincinnati, OH, November 2004.
139. **Pollack A.** “Radiotherapy for prostate cancer: role of androgen deprivation and lymph node irradiation.” University of Chicago, Chicago IL, November 2004.
140. **Pollack A.** “A Multi-institutional analysis of adjuvant and salvage radiotherapy after radical prostatectomy.” Invited abstract, special session on best abstracts from ASTRO. RSNA Annual Meeting, Chicago, IL, November 2004.
141. **Pollack A.** “Prostate cancer dose escalation: what is the role of lymph node treatment and androgen deprivation.” 4<sup>th</sup> S. Takahashi Memorial International Workshop on 3-Dimensional Conformal Radiotherapy, Nagoya Japan, December 2004.
142. **Pollack A.** “Prostate cancer radiotherapy: does androgen deprivation obviate the need for dose escalation using IMRT.” Henry Ford Health System, Detroit, MI, January 2005.
143. **Pollack A.** “IMRT in prostate cancer.” 2005 ASTRO Practicum—Implementing IMRT in Clinical Practice. Dallas, TX, February 2005.
144. **Pollack A.** “External beam radiation for prostate cancer: The importance of dose and technique and the role of prognostic markers.” UCSF Urologic Oncology Conference, San Francisco, CA February 2005.
145. **Pollack A.** “Chemoradiation for bladder cancer: As effective as surgery?” UCSF Urologic Oncology Conference, San Francisco, CA. February 2005.
146. **Pollack A.** “Radiation Therapy: Adjuvant versus salvage.” ASCO 2005 Multidisciplinary Prostate Cancer Symposium. Orlando, FL, February 2005.
147. **Pollack A.** “New technologies for local therapy of cancer: radiotherapy techniques. NCCN 10<sup>th</sup> Annual Conference, Hollywood, FL, March 2005.
148. **Pollack A.** “Prostate external beam radiotherapy (target volume definition including lymph nodes and postop) in combination with hormonal therapy.” ASTRO Spring Refresher Course 2005, Chicago, IL, April 2005.
149. **Pollack A.** “MDM2 expression predicts for prostate cancer outcome after radiotherapy and androgen deprivation: an analysis of RTOG 92-02. American Radium Society, 87<sup>th</sup> Annual Meeting, Barcelona, Spain, May 2005.

150. **Pollack A.** “External beam radiotherapy for intermediate prostate cancer”. American Radium Society, 87<sup>th</sup> Annual Meeting, Barcelona, Spain, May 2005.
151. **Pollack A.** 1) “Selection criteria for IMRT of the prostate.” 2) “Dose prescription, CTV and ORV definitions for the prostate” 3) “Expansion of CTV and ORV for IMRT of the prostate” 4) “IMRT treatment planning for the prostate” 5) “IMRT plan evaluation for the prostate” 6) Prostate cancer case discussions. IGIMRT @ Sea Practicum, Alaska, July 2005.
152. **Pollack A.** Prostate cancer target delineation. Third Annual Radiation Oncology Meeting, Dallas, TX, September 2005.
153. **Pollack A.** MDM2 expression is independent of p53 and Ki-67 in predicting prostate cancer outcome: an analysis of RTOG 92-02. ASTRO Annual Meeting, Denver, CO 2005.
154. **Pollack A.** Radiotherapy for prostate cancer, Cancer 2005 The Fox Chase Cancer Center Annual Symposium, Philadelphia, PA, October 2005.
155. **Pollack A.** Point/Counterpoint. Surgery versus radiation therapy versus no treatment for GU malignancies (Richard Greenberg/Alan Pollack), Cancer 2005 The Fox Chase Cancer Center Annual Symposium, Philadelphia, PA October 2005.
156. **Pollack A.** Clinical perspective: current challenges and future role of imaging. Innovative Solutions for Cancer Care Symposium, Washington, DC, October 2005.
157. **Pollack A.** Recent advances in external beam radiotherapy. New Perspectives on 2005 Prostate Cancer, 12<sup>th</sup> Annual Cancer Symposium, Bethesda, MD, November 2005.
158. **Pollack A.** Postoperative radiotherapy: adjuvant vs. salvage? New Perspectives on 2005 Prostate Cancer, 12<sup>th</sup> Annual Cancer Symposium, Bethesda, MD, November 3, 2005.
159. **Pollack A.** Radiotherapy treatment options for prostate and testicular cancers. Cancer Care Along the Continuum: Issues Facing Men. Fox Chase Cancer Center, Philadelphia., PA, November 2005.
160. **Pollack A.** Intensity-modulated radiation therapy: state of the art ù part II. 91<sup>st</sup> Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, IL, November 2005.
161. **Pollack A.** Rising PSA after surgery. RTOG Semi-Annual Meeting, Miami, FL, January 2006.
162. **Pollack A.** Treatment of surgical failure with radiotherapy. Current Problems in Urology – 4<sup>th</sup> Edition, Banff, Alberta, Canada, January 2006.
163. **Pollack A.** Adjuvant vs. salvage radiotherapy and technical considerations. Current Problems in Urology – 4<sup>th</sup> Edition, Banff, Alberta, Canada, January 2006.
164. **Pollack A.** The case in favor of ADT. Current Problems in Urology – 4<sup>th</sup> Edition, Banff, Alberta, Canada, January 2006.
165. **Pollack A.** “IMRT for prostate cancer.” 2006 ASTRO Practicum—Implementing IMRT in Clinical Practice. Irving, TX, February 2006.
166. **Pollack A.** “Proton therapy for prostate cancer. Is it cost effective?” Proton Beam Therapy Informational Symposium, Seattle, WA, February 2006.
167. **Pollack A.** “Hormonal therapy and EBRT.” 11<sup>th</sup> Annual Scottsdale Prostate Cancer Symposium, Scottsdale, AZ, March 2006.
168. **Pollack A.** “Post Radical Prostatectomy RT” and Session moderator (Adjuvant and Salvage Therapy).” 11<sup>th</sup> Annual Scottsdale Prostate Cancer Symposium, Scottsdale, AZ, March 2006.
169. **Pollack A.** “The role of androgen deprivation in the treatment of prostate cancer with external beam radiotherapy.” Philadelphia Roentgen Ray Society, Philadelphia, PA, April 2006.
170. **Pollack A.** “Targeted therapy in prostate cancer.” New York Roentgen Society Annual Conference, New York, NY, April 2006.

171. **Pollack A.** “Adjusted prostate cancer dose response.” 88<sup>th</sup> Annual Meeting of the American Radium Society, Maui, HI, May 2006.
172. **Pollack A.** Refresher course entitled “Treatment of organ confined, locally advanced and metastatic prostate cancer.” American Urological Association, Annual Meeting, San Francisco, CA, May 2006.
173. **Pollack A.** “Prostate Cancer: A Model for the Past, Present and Future of External Beam Radiotherapy.” Fox Chase Cancer Center 15<sup>th</sup> Annual Radiation Oncology Conference for Nurses, Therapists, and Dosimetrists, Philadelphia, PA, May 2006.
174. **Pollack A.** “Prostate Cancer Radiotherapy: The Importance of Local Control.” UMDNJ-Robert Wood Johnson Medical School/Cancer Institute of New Jersey, New Brunswick, NJ, September 2006.
175. **Pollack A.** “The importance of local control in prostate cancer: radiation, androgen deprivation and gene therapy.” University of Michigan, Ann Arbor, MI, September 2006.
176. **Pollack A.** “The importance of local control in prostate cancer: radiation, androgen deprivation and gene therapy.” Southwestern Medical Center, Dallas, TX, September 2006.
177. **Pollack A.** “New biomarkers for prostate cancer.” Delaware County Memorial Hospital, Drexel Hill, PA, September 2006.
178. **Pollack A.** “Hypofractionation for prostate cancer.” Varian Symposium at ASTRO 2006, Philadelphia, PA, November 2006.
179. **Pollack A.** “New advances for radiotherapy in prostate cancer.” Philadelphia Medicine International Video Conference (Brazil), December 2006.
180. **Pollack A.** “Optimizing local control in the treatment of prostate cancer with external beam radiotherapy: dose and androgen deprivation.” Geisinger Health System, Danville, PA, January 2007.
181. **Pollack A.** “Manipulating the apoptotic pathway to enhance prostate cancer response to radiation and androgen deprivation.” Geisinger Health System, Danville, PA, January 2007.
182. **Pollack A.** “Are cure rates higher with adjuvant as opposed to salvage postoperative radiotherapy for prostate cancer?” M.D. Anderson Cancer Center, Houston, TX, February 2007.
183. **Pollack A.** “Biomarkers in prostate cancer treated with radiotherapy” M.D. Anderson Cancer Center, Houston, TX, February 2007.
184. **Pollack A.** “Postoperative Treatment for Prostate Cancer” Montefiore Medical Center, New York, NY, April 2007.
185. **Pollack A.** “Prostate Cancer: Fox Chase Experience” NY Roentgen Society Meeting, New York, NY, April 2007.
186. **Pollack A.** “Higher cure rates with adjuvant, as opposed to salvage, postoperative radiotherapy for prostate cancer. 89<sup>th</sup> Annual American Radium Society Meeting, Amsterdam, Netherlands, May 2007.
187. **Pollack A.** “New Advances in Radiation Oncology.” 16<sup>th</sup> Annual Radiation Oncology Conference for Nurses, Therapists and Dosimetrists, Philadelphia, PA, May 2007.
188. **Pollack A.** “Molecular markers identified for prostate cancer therapy. San Francisco Radiation Oncology Conference, San Francisco, CA, July 2007.
189. **Pollack A.** “Application of Hypofractionation in the prostate,” AAPM Annual Meeting, Minneapolis, MN, July 2007.
190. **Pollack A.** “Antisense MDM2 and adenoviral E2F1 sensitize prostate cancer cells to androgen and radiation. IMPaCT Meeting, Atlanta, GA, September 2007.
191. **Pollack A.** “Image-guidance for the planning and delivery of radiation for prostate cancer. AdMeTech Meeting, Washington DC, September 2007.



192. **Pollack A.** “Radiation therapy post-prostatectomy: Adjuvant versus salvage.” New Technologies and Innovative Treatment Strategies for GU Malignancies, San Diego, CA, September 2007.
193. **Pollack A.** “Recent advances in external beam radiotherapy;” “Adjuvant therapy after surgery for high risk cancer;” “Hormone and radiotherapy for locally advanced or high risk prostate cancer.” New Perspectives on Prostate Cancer 2007, Bethesda, MD, October 2007.
194. **Pollack A.** “Image guided approaches and their importance in the optimization of outcomes.” ASTRO Annual Meeting, Los Angeles, CA, October 2007.
195. **Pollack A.** “Postoperative radiotherapy following prostatectomy: now that we know how it works, how should we do it?” Panel participant, ASTRO Annual Meeting, Los Angeles, CA, October 2007.
196. **Pollack A.** “Local persistence after radiotherapy for prostate cancer: A rationale for dose escalation to the dominant lesion.” RSNA Annual Meeting, Chicago, IL, November 2007.
197. **Pollack A.** “High risk prostate cancer: combined hormonal therapy and radiation therapy.” Panel Participant, Challenging Cases in Urologic Oncology, San Diego, CA, February 2008.
198. **Pollack A.** “Local persistence of disease after definitive therapy for prostate cancer.” Visiting Professor, Mayo Clinic, Rochester, MN, March 2008.
199. **Pollack A.** “State of the Art: Dose-scaling/proton radiation therapy.” Multidisciplinary meeting: prostate, kidney and bladder cancer, Nice, France, April 2008.
200. **Pollack A.** “Perception of the future in prostate cancer care.” Multidisciplinary meeting: prostate, kidney and bladder cancer, Nice, France, April 2008.
201. **Pollack A.** “Adjuvant or salvage radiation therapy: Current data and future plans. Congress on GU Malignancies. Washington, DC, July 2008.
202. **Pollack A.** “MRI Simulation for Prostate Cancer.” AAPM, Houston, TX, July 2008.
203. **Pollack A.** “Radiation as the primary treatment for localized disease.” 2<sup>nd</sup> Annual Perspectives in Urologic Oncology: A Case-Based Approach to Enhance Patient Management of Prostate, Renal and Bladder Cancer. Chicago, IL, September 2008.
204. **Pollack A.** “How to write a translational clinical protocol?” ASTRO 2008 Annual Meeting. Boston, MA, September 2008.
205. **Pollack A.** “eContouring for prostate” ASTRO 2008 Annual Meeting, Boston, MA, September 2008.
206. **Pollack A.** “Adjuvant and salvage post-prostatectomy radiotherapy for prostate cancer.” GU Oncology Conference, New York, NY, 2008.
207. **Pollack A.** “Radiation therapy: Current and evolving concepts.” Current Trends in GU Malignancies. New York, NY, October 2008.
208. **Pollack A.** “Prostate – anatomy, natural history and contouring.” RSNA Annual Meeting. Chicago, IL December 2008.
209. **Pollack A.** “IMRT for prostate cancer.” ASTRO Practicum on Advances in technology: Practical aspects on IMRT and Proton Therapy. Chandler, AZ, January 2009.
210. **Pollack A.** “Prostate cancer biomarkers and their respective molecular targets: An RTOG-Based Analysis.” Geneva, Switzerland, March 2009.
211. **Pollack A.** “Prostate Cancer.” ASTRO, Vancouver, Canada, April 2009.
212. **Pollack, A.** Prostate Advisory Board. Chicago, IL, July 2009.
213. **Pollack A.** “Salvage Radiation.” 9<sup>th</sup> International GU Congress, Washington, DC, July 2009.
214. **Pollack A.** “Functional imaging in the planning of external beam radiotherapy for prostate cancer.” Palm Beach, FL, July 2009.

215. **Pollack A.** “MRI Imaging for Prostate Cancer and The Implications for Radiotherapy” University of Texas Visiting Professor. Austin, TX, August 2009.
216. **Pollack, A.** “Role of radiation therapy for clinically localized prostate cancer.” Perspectives in Genitourinary Oncology, Chicago, IL, September 2009.
217. **Pollack, A.** “Expanding the utilization of MRI Prostate Imaging for Advanced Radiotherapy.” Chicago, IL, November 2009.
218. **Pollack, A.** Oral Presentation of Abstract “Hypofractionation for Prostate Cancer: Interim Results of a Randomized Trial.” Chicago, IL, November 2009.
219. **Pollack, A.** “Current Status of Dose Escalation in Prostate Cancer.” Cancun, Mexico, November 2009.
220. **Pollack, A.** “Boost Course: Anatomy & Contouring.” Chicago, IL, December 2009.
221. **Pollack, A.** “Pelvic Anatomy and MRI-based Treatment Planning in Prostate Cancer.” Orlando, FL, February 2010.
222. **Pollack, A.** “Treatment Planning and Contouring controversies for Intact Prostate and Post-Prostatectomy Scenarios.” Orlando, FL, February 2010.
223. **Pollack, A.** “Advances in external beam radiotherapy and brachytherapy in organ confined prostate cancer.” Sao Paulo, Brazil, April 2010.
224. **Pollack, A.** “Recent results of multimodal treatment in locally advanced prostate cancer.” Sao Paulo, Brazil, April 2010.
225. **Pollack, A.** “The role of adjuvant radiation therapy after radical prostatectomy for patients with undetectable PSA.” Sao Paulo, Brazil, April 2010.
226. **Pollack, A.** “Quality of life after local treatment for organ confined prostate cancer: comparison of results.” Sao Paulo, Brazil, April 2010.
227. **Pollack, A.** “Prostate Cancer Clinical Cases Discussion.” Sao Paulo, Brazil, April, 2010.
228. **Pollack, A.** “Efficacy results and quality of life after local treatment.” Sao Paulo, Brazil, April 2010.
229. **Pollack, A.** “Bladder cancer clinical cases discussion.” Sao Paulo, Brazil, April 2010.
230. **Pollack, A.** “Prostate: Anatomy/Planning.” Dallas, TX, May 2010.
231. **Pollack, A.** “Pelvis: Case Management Panel.” Dallas, TX, May 2010.
232. **Pollack, A.** “Nursing Management of Prostate Cancer: Focusing on patient centered care.” Miami, FL, June 2010.
233. **Pollack, A.** “Salvage and/or adjuvant post operative radiotherapy: What is the best option?” Nice, France, June 2010.
234. **Pollack, A.** “Hypofractionation applied to prostate cancer: What are the clinical evidences?” Nice, France, June 2010.
235. **Pollack, A.** “Managing patients with PSA recurrence after radical prostatectomy.” Washington, DC, July 2010.
236. **Pollack, A.** “Prostate cancer: Emerging approaches to treating the high-risk patient.” Bethesda, MD, September 2010.
237. **Pollack, A.** “Advances in the treatment planning and dose delivery for prostate cancer” Sao Paulo, Brazil, October 2010.
238. **Pollack, A.** “Treatment of intermediary risk.” Sao Paulo, Brazil, October 2010.
239. **Pollack, A.** “Post prostatectomy radiotherapy. When and how?” Sao Paulo, Brazil, October 2010.
240. **Pollack, A.** “Management of high risk prostate cancer (including postoperative XRT).” San Diego, CA, November 2010.
241. **Pollack, A.** “Emerging Trends in the Characterization and Treatment Decisions of Newly Diagnosed Prostate Cancer.” GU Cancers Symposium, Orlando, FL, February 2011.
242. **Pollack, A.** “Radiation Therapy IMRT/IGRT.” Advances in Prostate Cancer. Washington, DC, April 2011.

243. **Pollack, A.** “Modulating the SKP2/AR Axis in Men with Prostate Cancer.” RTOG, Philadelphia, PA, April 2011.
244. **Pollack, A.** “The role of MRI-based planning and treatment for IMRT and Proton Therapy.” ARS Annual Meeting, Palm Beach, FL, April 2011.
245. **Pollack, A.** “Intergrating Therapies for Intermediate and High Risk Prostate Cancer.” Moffitt Cancer Center Multidisciplinary Prostate Cancer Symposium, Tampa, FL, May 2011.
246. **Pollack, A.** “Functional MRI and Radiotherapy Dose Escalation for Prostate Cancer.” ALATRO Conference, Panama City, Panama, June 2011.
247. **Pollack, A.** “Management of High Risk Prostate Cancer (including postoperative XRT).” ASTRO – 53<sup>rd</sup> Annual Meeting, Miami Beach, FL, October 2011.
248. **Pollack, A.** “Recent Advances in External Beam Radiotherapy.” Prostate Cancer Symposium, Bethesda, MD, November 2011.
249. **Pollack, A.** “Adjuvant Postoperative Radiotherapy: Data from Clinical Trials.” Prostate Cancer Symposium, Bethesda, MD, November 2011.
250. **Pollack, A.** “Benefit of Combining Radiotherapy with Androgen Deprivation Therapy for Locally Advanced or High Risk Groups.” Prostate Cancer Symposium, Bethesda, MD, November 2011.
251. **Pollack, A.** “Stereotactic Radiotherapy for Prostate Cancer.” Synergy 2011, A Multidisciplinary Approach to Interventional Oncology, Miami Beach, FL 2011.
252. **Pollack, A.** “Managing Prostate Cancer with Radiation.” Breast and Prostate Cancer Update Conference, Canton, OH, November 2011.
253. **Pollack, A.** “Hypofractionated Therapy for Prostate Carcinoma.” ACRO, Ft. Myers, FL, February 2012.
254. **Pollack, A.** “MRI Applications for Prostate Cancer Diagnosis.” 5<sup>th</sup> Annual W.B. Ingalls Memorial Prostate Health and Cancer Seminar, Jupiter, FL, March 2012.
255. **Pollack, A.** “Clinical Trials and Tribulations: An Experience In GU Malignancies.” ARS 9<sup>th</sup> Annual Meeting. Las Vegas, NV, May 2012.
256. **Pollack, A.** “A Targeted Approach to Prostate Radiotherapy.” Florida Prostate Cancer Research Symposium, Orlando, FL, May 2012.
257. **Pollack, A.** “Radiation Therapy Following Radical Prostatectomy.” University of Miami Miller School of Medicine Conference, Miami, FL, June 2012.
258. **Pollack, A.** “Better targeting leads to improved radiotherapy outcomes.” The 20<sup>th</sup> Annual Chandler Society Resident and Fellow Research Forum, Miami, FL, June 2012.
259. **Pollack, A.** “Prospective Validation Of Diagnostic Tumor Tissue Ki-67 As The Most Significant Predictor Of Outcome In Men Treated For Prostate Cancer On A Randomized Trial.” ASTRO 54<sup>th</sup> Annual Meeting, Boston, MA, October 2012.
260. **Pollack, A.** “Management of High-risk Prostate Cancer (Including Postoperative XRT).” ASTRO 54<sup>th</sup> Annual Meeting, Boston, MA, October 2012.
261. **Pollack, A.** “Hypofractionated Raditherapy for Prostate Cancer: An Old Paradigm Revisited.” FROGG High Risk Prostate Cancer Workshop, Sydney, Australia, November 2012.
262. **Pollack, A.** “EBRT in high risk prostate cancer.” FROGG High Risk Prostate Cancer Workshop, Hobart, Tasmania, November 2012.
263. **Pollack, A.** “The management of post-prostatectomy patients with EBRT.” FROGG High Risk Prostate Cancer Workshop, Hobart, Tasmania, November 2012.
264. **Pollack, A.** “MRI Guided Prostate Biopsy: Applications and Advances.” 6<sup>th</sup> Annual W.B. Ingalls Memorial Prostate Health and Cancer Seminar, Jupiter, FL, March 2013.
265. **Pollack, A.** “UM Trials: LEAD; Extreme Hypofractioning; HEAT.” Florida Prostate Cancer Research Symposium, Orlando, FL, March 2013.

266. **Pollack, A.** “Hypofractionation for Prostate Cancer: An Old Pardigm.” Texas Radiological Society Centennial Meeting, Houston, TX, April 2013.
267. **Pollack, A.** “Interesting Case Review.” Visiting Professor, Texas Radiological Society Centennial Meeting, Houston, TX, April 2013.
268. **Pollack A.** “Hypofractionation for Prostate Cancer: An Old Paradigm Revisited.” Winship Grand Rounds, Emory University School of Medicine Department of Radiation Oncology, Atlanta, Georgia, July 2013.
269. **Pollack A.** “Management of Prostate Cancer Patients with High Risk Pathologic Features or a Rising PSA Post-Prostatectomy.” University of Pennsylvania, Philadelphia, Pennsylvania, November 2013.
270. **Pollack A.** “Hypofractionation for Prostate Cancer: An Old Paradigm Revisited.” University of Pennsylvania, Philadelphia, Pennsylvania, November 2013.
271. **Pollack A.** “Recent Advances in External Beam Radiotherapy.” New Perspectives on Prostate Cancer 2013. Washington Adventist Hospital. Takoma Park, Maryland. November 2013.
272. **Pollack A.** Multiparametric MRI for prostate cancer. W.B. Ingalls Memorial Annual Prostate Cancer meeting, Scripps, Jupiter, FL 2012-2013
273. **Pollack A.** “Benefit of Combining Radiotherapy with Androgen Deprivation Therapy for Locally Advanced or High Risk Groups.” New Perspectives on Prostate Cancer 2013. Washington Adventist Hospital. Takoma Park, Maryland. November 2013.
274. **Pollack A.** “Biomarker Driven Risk Assessment for Prostate Cancer Treated with External Beam Radiotherapy.” Columbia University College of Physicians and Surgeons, New York, November 14, 2014.
275. **Pollack, A.** “Adjuvant Radiotherapy x Early Salvage Radiotherapy: What’s the Gold Standard?” XXI Rio Journey of Urology Conference in Brazil, November 19, 2014.
276. **Pollack, A.** “Primary Bladder Preservation Treatment: An Excellent Alternative to Cystectomy?” XXI Rio Journey of Urology Conference in Brazil, November 19, 2014.
277. **Pollack, A.** “Radiotherapy for Stage II and Stage I Progression after Active Surveillance for Seminoma of the Testis.” XXI Rio Journey of Urology Conference in Brazil, November 19, 2014.
278. **Pollack, A.** Primary Prostate Cancer Precision Radiotherapy, Tufts University, September 18, 2015.
279. **Pollack, A.** “The Role of Quantitative Imaging in the Era of Precision Medicine” Radiomics Meeting, Clearwater, FL, October 26, 2015
280. Multiparametric MRI for Prostate Cancer, Prostate cancer Advisory Council, Gainesville, FL
281. **Pollack, A.** “Prostate Cancers – Clinical Management.” University of Miami Miller School of Medicine – CAB 715 Graduate Program in Cancer Biology, March 24, 2016.

## **28. Thesis and Dissertation Advising/Post-doctoral student supervision**

### **Graduate Student Committee, Chair:**

Catherine S. Wu, M.S., Univ. of Texas at Houston, Masters in Biology	1994-1996
Michael Durante, M.D./Ph.D., seeking a Ph.D. in Cancer Biology University of Miami Miller School of Medicine	2013-Present

### **Graduate Student Committees:**

David Boothman, Ph.D., University of Miami, Ph.D. in Microbiology and Immunology	1983-1986
Cindy Taylor, Ph.D., University of Miami,	

Ph.D. in Microbiology and Immunology	1983-1986
Victor Howard, M.S. Univ. of Texas at Houston, Masters in Medical Physics	1994-1996
Dee-Ann Radford, M.S., Univ. of Texas at Houston, Masters in Medical Physics	1999-2001
Melita Nasca, Ph.D. Candidate, Univ. of Texas at Houston, Examining Committee	1999-2000
Brian Deegan, Ph.D., University of Miami	2011
Ali Saeed, Ph.D., University of Miami	2013

## **VII. SERVICE**

### **29. University Committee and Administrative Responsibilities [with inclusive dates]**

#### **Administrative Responsibilities (Since 1999):**

Faculty Senate, Member, MDACC	1994-2000
Graduate School of Biomedical Sciences Committee, Assoc. Member, MDACC	1995-2001
Associate Medical Director, Sarcoma Center, MDACC	1996-1999
Tumor Registry Steering Committee, Member, MDACC	1997-2001
GU Database Committee, Member, MDACC	1997-2001
Outcomes Steering Committee, Member, MDACC	1998-2001
Director, Residency Training Program, MDACC	1998-2001
Chair, Nominating Committee for Gilbert Fletcher Society	1999-2000
Section Head, Genitourinary Radiation Oncology, MDACC	1999-2001
Associate Medical Director, Genitourinary Center, MDACC	2000-2001
Chairman, Department of Radiation Oncology, FCCC	2001-2008
Program Leader, Prostate Cancer Working Group, FCCC	2001-2007
Executive Committee of Staff, FCCC	2001-2008
Ambulatory Care Committee, FCCC	2001-2008
Chair, 8HP Utilization Committee, FCCC	2003-2004
Promotion and Tenure Committee, FCCC	2003-2008
Advisory Committee, Geisinger Health System/FCCC Strategic Alliance	2004-2008
Honorary Chair, Employee United Way Campaign, FCCC	2004
Associate Director of Community Physician Relations, SCCC	2008-2011
Medical Executive Committee, UMH	2009-2013
Dean's Quarterly Medical School Executive Group, UM	2008-2013
Dean's Research Committee, UM	2008-2013
Co-leader, SDG Physician Leadership, SCCC/UM	2008-2013
Medical Executive Committee, UMHC/SCCC	2008-Present
Medical Executive Committee, JMH	2008-Present
Member, UMMG Leadership Council, UM	2008-Present
Member, Executive and Senior Leadership Committees, SCCC/UM	2008-Present
Member, Scientific Steering Committee, SCCC/UM	2008-Present
Leader, Radiation Oncology Operations Committee, SCCC/UM	2008-Present
Co-leader, GU Malignancies Program, SCCC/UM	2008-2014
Theme leader, Tumor Biology program, SCCC/UM	2014-Present

### **30. Community Activities [with inclusive dates]**

Periodic Rectal screening examinations – Presbyterian Church, Philadelphia, PA	2002-2008
Periodic lectures to prostate cancer support groups	2001-2008